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Abstract 
Aptamers have emerged as potential affinity agents that rival or complement 
antibodies in developing diagnostic assays for disease detection. We have demonstrated 
the use of PMMA microfluidic devices for conducting rapid affinity microchip CGE of a 
target protein using aptamers as the affinity probes with an electrophoresis development 
time of <2 min. Migration times were reproducible for thrombin complexes and free 
aptamers in CGE buffer with device-to-device RSD variations below 10%.  By removing 
salts from plasma and adding an unlabeled random sequence oligonucleotide to the 
plasma, thrombin was detected in plasma. This method can be easily adapted to high-
throughput parallel screening of plasma samples in multi-channel polymeric 
microdevices.  
The expression of rEpCAM in bacteria and mammalian cells was investigated with 
results showing successful expression in the mammalian systems, while protein 
expression in the bacteria was inhibited. Higher and prolonged expression levels were 
obtained in Cos 7 cells as compared to BHK and Hep2 cells due to episomal expression 
in Cos 7 cells. By combining a one-step IMAC procedure with electrophoresis and 
electro elution a more selective approach to obtaining electrophoretically pure rEpCAM 
was achieved.  
We developed dual-aptamer sandwich assays for thrombin and PDGF-BB targets on 
PMMA substrate using UV modification with a one-step EDC/NHS coupling reaction. 
Results indicate that the use of high EDC concentrations lead to faster immobilization 
and increased coverage density with a shorter sandwich assay development time.   The 
 xv
assays were sensitive for both proteins and showed linearity in fluorescence response to 
changing protein concentration.  
 
Single molecule detection methods provide high sensitivity techniques in which 
aptamers can find use. We have demonstrated the use of two aptamers in a FRET-based 
assay for the detection of low levels of thrombin.  Sensitivity and reliability of the 
aptamer smFRET assay depends on complex formation and stability.  Due to the 
dissociation constants of the aptamers, single molecule events detected were below the 
calculated value for a 6 pM concentration of thrombin. Future work will involve 
adjusting the single molecule system by the use of pinholes to enable analysis of higher 
sample concentrations. 
 1
Chapter 1 Aptamers: A Class of Affinity Compounds with Potential 
Applications in Therapeutics and Disease Diagnosis 
 
1.1 Introduction 
Affinity agents, such as antibodies, are the central component in many bioanalytical 
techniques.   This is due to their high level of specificity and selectivity for the recognition of 
targets embedded in complex sample matrices.  Antibodies are proteinaceous materials and are 
generated in vivo through induction of an immune response in animal hosts or by hybridoma 
technology.1, 2  Their use in the development of bioanalytical techniques suffers from certain 
disadvantages however, including their protracted method of production, the need for relatively 
large targets to induce an immune response in the host, cross reactivity of antibodies with 
structurally similar analytes and instability of their tertiary protein structures leading to short 
shelf-life.  Alternatives to antibodies have been studied which include peptides and nucleic acid 
aptamers.  The latter group of newly developed affinity agents, aptamers, hold promise as viable 
alternatives to antibodies in many bioanalytical methods requiring an affinity agent.1 
Aptamer-based molecular recognition applications are rapidly developing into a field that 
is projected to be competitive with antibody-based biosensors, immunoassays, and other 
analytical formats currently in use.3  Aptamers (derived from the Latin words aptus-to fit and 
meros-particle)4 are artificial receptors, primarily DNA or RNA sequences between 15 to 60 
bases in length, which are generated in vitro toward  target molecules ranging in size from 100 
daltons 5, 6 to as large as whole cells.7, 8  They are short single-stranded sequences with specific 
and complex three-dimensional structures comprised of stems, loops, bulges, hairpins, triplex or 
quadruplex motifs.9  The high affinity displayed by aptamers to a variety of molecules can be 
attributed to their ability to incorporate small molecules into their three-dimensional nucleic acid 
structure, or to integrate into the structure of larger molecules such as proteins, using 
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noncovalent interactions. These interacts include but are not limited to stacking of aromatic rings, 
electrostatic and/or van der Waals interactions, hydrogen bonding, or from a combination of 
these effects.10, 11  Aptamers can also adopt an induced-fit mechanism when binding to their 
targets in solution.  Many aptamers exhibit binding affinities similar to monoclonal antibodies 
with dissociation constants (KBDB) in the nanomolar to micromolar range for small molecules and 
picomolar to nanomolar range for larger targets such as proteins.9  
Table 1.1 provides a literature survey of aptamers that have been developed for selected 
targets and the dissociation constants. These targets range from as small as divalent metal cations 
(zinc and nickel) or organic molecules such as malachite green, ethanolamine and theophylline, 
to large targets such as enzymes, antibodies and leukemia cells (see Table 1.1). Also, aptamers 
can distinguish between chiral molecules through the design of the aptamers for recognition of a 
specific stereoisomer. In a study by Michaud et al (2003) a DNA aptamer capable of recognizing 
the D-enantiomer of  an oligopeptide, arginine-vasopression, was used as a stationary phase for 
liquid chromatographic separation of the L and D stereoisomers of the oligopeptide, in which the 
D form was retained by the column while the L form eluted in the void volume.12   
Aptamers can be an attractive alternative to antibodies in a variety of research 
applications due to their potential as molecular recognition elements with certain advantages 
over their antibody counterparts.13  Unlike antibodies, aptamers have the benefits of being 
chemically and thermally stable, can be selected toward a wider range of targets (see Table 1.1) 
and are generated by in vitro solid phase synthesis techniques without the constraints of in vivo 
generation required for antibodies.13   
The selection process allows generation of aptamers towards specific regions of the target 
whereas the antibody generation process is subject to the immune system of the animal it is 
produced in, which means researchers have very little control over the exact epitope an antibody 
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can be raised against.13  Surface immobilized aptamers can be easily regenerated for repeated use 
in devices without undergoing denaturation as is observed with antibodies.3  Also, the smaller 
size, ease of modification and single stranded structure of nucleic acid aptamers allow their 
immobilization on surfaces in a more highly ordered form compared to antibodies, making them 
more appropriate for techniques requiring immobilization of affinity agents onto solid support.  
The production of aptamers by solid phase synthesis also enables chemical modifications to be 
made during production, such as incorporation of functional groups or structural alterations, to 
increase stability of the molecule without affecting function.1  The in vitro selection process of 
aptamer generation makes it advantageous for quick aptamer selection toward newly discovered 
biomarkers even under conditions similar to those used in assays for which the aptamers are 
being developed.9, 14 
1.2 U The Aptamer Generation Process 
The aptamer selection technique, dubbed Systematic Evolution of Ligands by 
Exponential enrichment (SELEX), is an iterative method in which combinatorial elements (i.e. 
different sequences of DNA or RNA) are incubated with a target for selection of library elements 
that bind tightly to the target.15, 16  The unbound fraction is partitioned off and the bound fraction, 
once eluted from the target, amplified by PCR for another round of selection.  The process is 
repeated until an enriched pool of tightly binding oligonucleotides is obtained. The pool of 
oligonucleotides is cloned and analyzed via sequencing to determine the nucleotide content of 
the newly generated aptamers (see Figure 1.1).  Each step of the SELEX process is of great 
importance in order to produce aptamers with very high specificity or low K BDB values.17 
1.2.1 The SELEX Library  
The combinatorial library is usually made up of ribonucleic acids 18 or deoxyribonucleic acids 
(DNA) and consists of random synthetic sequences of  20 – 80 nucleotides flanked by  
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Table 1.1 Examples of targets used for aptamer selection, the types of aptamers generated and 
their dissociation constants.  
 
Targets Type of aptamer  KBd B References  
ZnP2+P  RNA  1.2 mmol/L  Ciesiolka et al. (1995)19  
Ni P2+P  RNA  0.8–29 mmol/L Hofmann et al. (1997)20  
Ethanolamine  DNA  6–19 nmol/L  Mann et al. (2005)6  
Theophylline  RNA  100 nmol/L  Jenison et al. (1994)21  
Malachite green  RNA  1 mmol/L  Grate and Wilson (2001)22 
Organic dyes  DNA  33–46 mmol/L Ellington and Szostak (1992)23  
Ricin toxin  DNA  58–105 nmol/L Tang et al. (2006)24  
L-tyrosinamide  DNA  45 mmol/L  Vianini et al. (2001) 25 
a-Thrombin  DNA  200 nmol/L  Bock et al. (1992)26  
  RNA  <1–4 nmol/L  White et al. (2001)27  
Bovine thrombin  RNA  164–240 nmol/L  Liu et al. (2003)
28  
Immunglobulin E  DNA  23–39 nmol/L  Mendonsa and Bowser (2004)29  
PDGF  DNA  0.1 nmol/L  Green et al. (1996)30  
VEGF  RNA  0.1–2 nmol/L  Jellinek et al. (1994)31  
TTF1  DNA  3.3–67 nmol/L Murphy et al. (2003)32  
HGF  DNA  19–25 nmol/L  Saito and Tomida (2005)33 
L-Selectin  DNA  1.8–5.5 nmol/L Hicke et al. (1996)34  
Taq DNA polymerase  DNA  0.04–9 nmol/L Dang and Jayasena (1996)35  
Prion protein (PrPc)  RNA  0.1–1.7 nmol/L Proske et al. (2002)36  
Hepatitis C virus RdRp  DNA  1.3/23.5 nmol/L  Jones et al. (2006)
37  
Tumour marker MUC1  DNA  0.1–34 nmol/L Ferreira et al. (2006)38  
U251 glioblastoma 
cells/tenascin-C  RNA  5 nmol/L  Hicke et al. (2001)
39  




predetermined sequences at the 5’ and 3’ ends for polymerase chain reaction (PCR) 
amplification of DNA, transcription or reverse transcription followed by PCR (RT-PCR) when 
RNAs are used as the recognition element.9 The complexity of the library depends intimately on 
the number of nucleotides in the random region.  For example, the theoretical number of unique 
sequences for a library containing “n” nucleotides will be 4Pn P, thus a thirty random nucleotide 
sequence would have 4 P30P (~1.2 x10P18P) unique sequences.15, 41  However, most libraries are 
generated to contain between 10P13 P to 10P15P individual sequences.13  The oligonucleotide libraries 
used for aptamer selection can be directly utilized in the SELEX process, with some researchers 
preferring to PCR amplify and purify the library prior to the start of SELEX to eliminate 
damaged DNA or un-amplifiable sequences that may interfere with the selection process.42  The 
use of RNA libraries, however, requires the design of forward primers and oligonucleotide 5’ 
regions with a T7 promoter sequence for conversion of DNAs to RNAs before the selection step.  
Amplification of the bound RNA oligonucleotides occurs by RT-PCR and transcription of the 
cDNA back to RNA for subsequent selection steps.9  
Important considerations in library design to ensure success in aptamer selection include 
the length of the random sequence, which affects the amplification process.43  It has been 
observed that long sequences of approximately 80 to 100 bases provide high structural 
complexity during the binding process compared to shorter oligonucleotide strands of about 20 
to 40 bases, especially for targets not known to bind nucleic acids naturally.3, 9, 42  However, long 
oligonucleotide strands with 80 bases or more tend to produce lower yields of full length 
products and generate by-products during the PCR amplification process.43 Truncated versions of 
the oligonucleotide strands occur as the number of PCR cycles increases above 20 when the PCR 
product concentration is increased to between 20- 50 nM and serve as templates from which 
single stranded/ double stranded DNA (ss-dsDNA) by-products are produced.  Variations in the 
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melting temperatures due to guanine and cytosine compositional differences also cause some 
members of the library not to be amplified if the strands are not sufficiently unfolded to allow 
primer binding.43   
 
Figure 1.1: In vitro selection of target-specific aptamers using SELEX.  The cyclic selection 
process uses a synthetic oligonucleotide library made up of either ssDNA or RNA molecules that 
are incubated with the target.  Following removal of the non-bound fraction of the library, the 
bound DNA/RNA sequences are eluted from the target and amplified and this pool subjected to 
the appropriate number of cycles.  The final pool of oligonucleotides is cloned and sequenced.  
Each cycle will produce aptamers with higher specificity and binding strength to the selected 
target.   
 
Thus, to circumvent these problems researchers PCR amplify the starting library and purify the 
resulting amplicons prior to initiation of the SELEX process.9 
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Because oligonucleotides are composed of only 4 different nucleotide bases, this limits 
the possible randomized combinations available in producing these libraries compared to the 
alternative synthetic recognition element, peptoids, which are generated from a pool of 20 
different amino acids. However, chemical modifications can be introduced into the DNA/RNA 
sequences to increase library complexity and also provide conformational stability and/or confer 
nuclease resistance characteristics. Typical modifications include replacement of the 2’-hydroxyl 
group on the ribose of pyrimidine nucleotides with a primary amine,  introduction of a fluoride 
or methoxy group to create nuclease resistant RNA (see Figure 1.2).P44,45 P   Another means of 
stabilizing nucleic acid aptamers is to use stereoisomers of the target in the selection process 
with subsequent synthesis of the mirror image of the generated aptamer, referred to as 
spiegelmers.46  By substituting D-ribose with L-ribose the nuclease resistance of RNA aptamers 
can be increased as well.47  Alternatively, the phosphate backbone can be altered by replacing 
non-binding oxygen with a sulfur group to increase nuclease resistance.48  Carbon positions 5 
and 8 on the pyrimidine and purine bases, respectively, can also be modified with amino acid 
groups to generate aptamers capable of tightly binding anionic targets.9  Modified nucleotides, 
such as 5-bromouracyl and 5-iodouracil, have been incorporated into aptamer sequences to allow 
photo-crosslinking of aptamers to targets.49  With modifications to nucleotide bases, the 
complexity of a combinatorial library can be further increased to extend the range of target 
diversity to which aptamers can be generated.9 
1.2.2 Aptamer Selection Targets  
Since its inception in 1990, SELEX has been applied to different classes of targets 
ranging from small molecules such as divalent cations,20 ethanolamine,6 and antibiotics50 to large 
complex targets such as proteins,26, 29 mixtures of targets (found as aggregates or on cell 
surfaces) and whole cells.3, 13, 40  Aptamers can be generated toward targets that are naturally 
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associated with nucleic acids such as nucleotides, cofactors and DNA binding proteins and for 
targets not naturally associated with nucleic acids (organic dyes and growth factors).4, 23, 30, 51   
 
 
Figure 1.2 Possible modifications carried out on nucleotides in generating libraries for SELEX.  
Modifications on the ribose sugar create nuclease resistant oligonucleotides while the bases can 
be modified depending on the required function. (Adapted from Jayasena, 1999)1 
   
A large percentage of aptamer selections carried out to-date have been directed toward 
protein or peptide targets, both free and extra-cellular domain of membrane bound proteins, due 
to the large multi-functional surfaces possessed by proteins making them excellent targets for 
aptamer selection.26, 34  The wide variety of targets used in aptamer selection gives an indication 
of the wide-range applicability of these recognition elements to virtually any target. However, in 
order to generate highly specific and tightly binding aptamers for a given target certain 
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requirements need to be met. For example the target should be present at sufficient enough levels 
and of very high purity to prevent enrichment of non-specifically interacting oligonucleotides.9   
Characteristics that enhance aptamer selection include possession of positively charged 
groups (e.g. primary amines), presence of hydrogen bond donors and acceptors and planar 
structures (as found in aromatic groups).  These allow the aptamers to bind to the target through 
a combination of interactive forces such as shape complementarity, aromatic structure and 
nucleotide stacking interactions, electrostatic and hydrogen bonding interactions.10, 11, 52   
 
Figure 1.3 The quartet structure formed by guanine molecules in thrombin aptamers: (A) the 
quadruplex stabilized by potassium ions and; (B) a diagram depicting the three-dimensional non-
canonical structure adopted by the thrombin aptamers when binding to the exosites. 
 
Another interesting feature of aptamers is their ability, in the presence of their targets and 
on formation of the binding complex, to undergo adaptive conformational changes.  Three-
dimensional structure formation enables an aptamer to encapsulate small targets while for higher 
molecular weight targets different surface sub-structures on the target may be involved in the 
aptamer binding process.9, 11  For example, the thrombin aptamers, HD1 and HD22, bind to its 
cationic exosites through the formation of a G-quartet structure (see Figure 1.3).   
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Highly anionic or hydrophobic targets are less likely to serve as good targets for aptamer 
selection due to molecular repulsion and electrostatic considerations. To minimize these effects, 
modifications can be made to the combinatorial library to create cationic or hydrophobic 
functional groups in these strands to enhance their affinity toward these targets.  Protein 
biomarkers serve as good targets for aptamer selection due to the multifunctional surface groups 
that allow oligonucleotides to bind easily.  Current advances in protein engineering allow for the 
rapid generation of proteins or segments of proteins engineered with fusion tags32 that can be 
used as targets for affinity selection processes and biochemical interaction processes.  Aptamer 
selection against some protein biomarkers are thus carried out with recombinant proteins as 
targets. For example, an N-terminus hexahistidine-tagged recombinant of a thyroid transcription 
factor was immobilized onto magnetic metal chelating resins and used as a target for SELEX  
with the derived aptamer characterized by surface plasmon resonance, enzyme linked assays, 
western blot and  affinity purification.32  
1.2.3 Selection Process  
The basic concepts of SELEX developed by Kramer et al.53 were independently utilized 
by two groups4, 17 in the early 1990s to develop the general approach for aptamer generation 
from a random oligonucleotide library.54   Since then, numerous variations to the original Tuerk 
and Gold SELEX method (1990) have been developed.  This has given rise to different names 
for the SELEX process depending on the factors used for the aptamer selection.  For example, 
counter-SELEX involves affinity elution of bound aptamers with structural analogs to eliminate 
aptamers that bind closely-related compounds.1 Cell-SELEX involves selection of aptamers 
against whole-cell targets as was originally done for the generation of the Tenasin C aptamer.55 
An example of the cell-SELEX process was recently demonstrated in a study by Shannguan et al 
(2006) to generate aptamers for cancer diagnosis. Aptamers were derived toward a lymphoblastic 
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leukemia cell-line (CCRF-CEM) through a counter-SELEX process involving the use of human 
Burkitt’s lymphoma cell line (Ramos) as the negative target.40  Figure 1.4 shows the cell-SELEX 
process. During the selection process, the unbound fraction of the combinatorial library from the 
counter-SELEX process using Ramos cells was used in the selection of high affinity aptamers 
toward the CCRF-CEM target. The aptamers were used in flow cytometry studies to determine 
their ability to bind specifically to membrane proteins on the surfaces of the leukemia cells.40 
Direct interaction of a target with a combinatorial library for a given time period with subsequent 
removal of the unbound oligonucleotides forms the selection step of the SELEX process.  This 
process is application-oriented and does not require in-depth knowledge of the characteristics of 
the target. Various methods exist for enhancing the incubation and partitioning of the bound and 
unbound fractions of the library during each selection round.  These comprise methods that do or 
do not require target immobilization.  Target immobilization typically involves column 
chromatography in which targets, such as proteins and dye molecules, are immobilized through 
affinity interaction or by cross-linking them to support matrices.4, 32 This is the most 
conventional method for target immobilization, but requires large amounts of sample to allow 
efficient loading onto the columns.56, 57  However, by using magnetic beads and affinity 
immobilization, smaller sample sizes can be used and in parallel format for high throughput 
screening of different targets in both manual and automated formats, which also enables 
elimination of several intermediate steps such as centrifugation and filtration.54 
Selection methods requiring no target immobilization include membrane filtration, 
capillary electrophoresis (CE-SELEX), Surface Plasmon Resonance, centrifugation, and flow 
cytometry.54  Membrane filtration selection utilizes nitrocellulose membranes with various 
molecular weight cut-offs to separate unbound oligonucleotides from nucleic acid-target 
complexes after pre-incubation of a combinatorial library with the target of interest (usually a 
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protein).  After washing to remove unbound oligonucleotides the bound oligonucleotides are 
eluted and amplified for the next round of SELEX.  
 
 
Figure 1.4 A schematic of the cell-SELEX process involving counter-SELEX using negative 
control cells to eliminate non-specifically interacting aptamers during the selection process. The 
aptamer enrichment steps for the target cells involve utilization of the unbound pool of aptamers 
from the counter-SELEX process. (Adapted from Shangguan et al. (2006))40 
 
Another technique demonstrated by Mosing et al, (2005) and Tang et al (2006) is 
selection using capillary electrophoresis (CE-SELEX).24, 58  This technique enables faster 
generation of aptamers in as few as four rounds.  For example, in the studies carried out by Tang 
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and co-workers, aptamers were derived against ricin using two in vitro techniques, affinity 
chromatography and CE-SELEX. In this study, 10 pM ricin was incubated with the ssDNA pool 
for 30 min and separated by CE.  Their results showed that the rate of oligonucleotide 
enrichment increased to 60.2% after two rounds of SELEX compared to 38.5% obtained by 
conventional SELEX, making CE-SELEX a faster process for aptamer selection against 
targets.24 The CE-SELEX method has also been employed in aptamer selection processes for 
producing high affinity aptamers against human immunoglobulin E (IgE),29 and HIV reverse 
transcriptase.58  
1.2.4 Amplification, Elution and Characterization of Aptamers 
One major advantage of aptamer selection is the ease of amplification of the bound 
oligonucleotides using biosynthetic processes, such as, PCR (DNAs) and RT-PCR (RNAs).  In 
the enrichment and identification steps associated with SELEX, bound oligonucleotides need to 
be amplified due to the complexity of the starting library. Although a high concentration of 
starting library can be used, the concentrations of the binding sequences will initially be very low 
due to the large number of diverse sequences present, requiring amplification and enrichment in 
subsequent processes to increase the amount of high affinity sequences in each round.  The 
amplification process can be carried out using modified primers to aid in purification and 
detection of the aptamers.  DNA aptamers only require PCR amplification using Taq polymerase, 
while the RNA aptamers require RT-PCR and subsequent transcription.42 Thus, RNA aptamer 
SELEX requires the use of primers with a T7 promotor sequence.   
For subsequent rounds of selection, the amplified DNA must be in single-stranded form 
and unfortunately, PCR generates double-stranded products. As such, techniques must be used to 
generate the prerequisite single-stranded form. Reverse primers functionalized with biotin can be 
designed to help with immobilization of amplified double stranded DNA (dsDNA) through 
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avidin/biotin interaction with subsequent release of the single stranded DNA (ssDNA) after 
denaturing the immobilized dsDNA.32  Other techniques for generating the single stranded 
construct include asymmetric PCR in which an excess of one primer is used to generate more of 
one type of ssDNA, usually the binding strand.59 
Elution strategies for releasing bound aptamers from their targets include heat treatment, 
addition of urea, sodium dodecyl sulfate (SDS) or ethylene diamine tetra acetic acid (EDTA) to 
disrupt complexation. The use of competitive binders has also been reported in the elution step to 
displace a bound target.  Selection rounds range between 4 to 20 cycles after which the amplified 
sequences are cloned and sequenced to characterize the binding oligonucleotide strands.13 The 
number of different aptamers obtained depends on the target and stringency of the selection 
process and ranges between 1 and 10 P6 P.  To characterize the aptamers, software programs have 
been developed, such as CLUSTAL W, to help align sequences to determine homology and 
mfold for secondary structural conformation determination.9 
1.3 Challenges Associated with Aptamers 
In spite of the promising research on aptamers and their generation, there are a few 
disadvantages associated with them.  One of the main disadvantages is that this technology is a  
relatively new area compared to antibodies which have been very widely studied, and as such, 
not many high affinity aptamers are commercially available.9   Also, not all targets are suitable 
for aptamer selection due to the absence of the necessary structural motifs present in the target 
that provide molecular interactions for binding to apatmers. For example, anionic and 
hydrophobic targets are not suitable for aptamer selection unless modifications are made to the 
bases (see Section 1.2.2). Although aptamers can be selected toward a wide range of targets, 
research has indicated that aptamers with micromolar to millimolar  dissociation constants are 
primarily derived for smaller targets (see Table 1.1), which implies lower affinities when 
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compared to antibodies.9  Thus more information is required on the interactions involved in 
generation of high affinity aptamers and developing a standard protocol for generating 
aptamers.9  For example, in terms of standardizing a protocol for aptamer arrays,  Collet et al. 
(2005) observed that a single buffer systems could not be used to allow different aptamers to 
bind efficiently to corresponding targets.60  Also, modifications to aptamers to confer nuclease 
resistance also add to the cost of the aptamers produced.   
1.4 Applications of Aptamers 
1.4.1 Therapeutic and In Vivo Diagnostic Applications 
Aptamers can be adapted to a variety of therapeutic and in vivo diagnostic applications 
where affinity agents are required.  In the area of therapeutics, aptamers are rapidly catching up 
with antibodies.61  The first Food and Drug Administration 62 approved aptamer for therapeutic 
function is the vascular endothelial growth factor aptamer which has been approved for treatment 
of macular degeneration.61, 63  In the area of in vivo diagnostics, aptamers are in general more 
suitable than antibodies for conducting in vivo imaging for disease detection due to the smaller 
size of aptamers compared to antibodies, which provides a faster clearance rate in the body for 
agents that may be toxic.  Aptamers also have lower immunogenicity and can be modified to 
extend their half-life in the blood.9 
1.4.2 In vitro Diagnostic Applications 
In vitro diagnostics (IVD) has been an area of considerable innovation and scientific 
advancement over the past decade in an attempt to provide medical professionals with tools to 
enable the acquisition of obtain objective information about disease states in order to effectively 
and rapidly treat patients.5, 64 Some of the most significant promises come from the utilization of 
validated biomarkers to predict a patient’s likelihood of responding to a medicine or avoiding 
certain side effects.5  With the yearly growth in the market value of IVD, substantial amounts of 
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resources are being invested into diagnostic research aimed at identifying and validating new 
biomarkers and the detection science involved in IVD tests.64, 65 
IVD tests can generally be classified as medical tests conducted in a controlled 
environment, such as a test tube, outside of a living organism. The FDA’s definition of IVD 
products are those reagents, instruments and  systems intended for use in diagnosis of disease or 
other conditions, including a determination of the state of health, in order to cure, mitigate, treat, 
or prevent disease or its sequelae (chronic condition).62, 65 These include analytical and 
bioanalytical techniques used in clinical laboratories like mass spectrometry, immunoassays and 
electrophoresis;66 and point-of-care (POC) devices, such as biosensors based on several different 
transduction modalities such as acoustic, optical and electrochemical detection.64  
 A new IVD classification category was introduced by the FDA in 1996 as a modification 
to its regulatory oversight in the area of IVDs. This category called the analyte-specific reagents 
(ASRs) include antibodies, both monoclonal and polyclonal, specific receptor proteins, nucleic 
acid sequences and similar reagents which, through specific binding or chemical reaction with 
substances in a specimen, are intended for use in a diagnostic application for identification and 
quantification of an individual chemical substance or ligand in biological specimens.65  This new 
category was based on the recognition by the FDA that ASRs are the active ingredients of in-
house tests, which when used in combination with general purpose reagents and laboratory 
instruments, could be the basis for new assays, which could benefit public health.  
Antibodies are currently the most widely available agents used in affinity-based 
diagnostic techniques that can use biosensors, arrays or bioseparations as the functional platform 
for the diagnostic. However, aptamers are rapidly penetrating this area.67  Because of their 
robustness compared to antibodies in terms of their ability to withstand extreme pH, temperature 
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and regeneration conditions that induce denaturing, they may be more suited for creating 
affinity-based assays using the afore mentioned techniques.68  
Biosensors are devices that couple a biological recognition element with a physical 
transducer to allow for the detection of a target.  Commonly used transducers are optical, 
electrochemical or mass sensitive devices that generate light, current or frequency signals for 
quantitative or semi-quantitative information.13  Using aptamers as recognition elements, several 
biosensors have been developed to analyze a variety of targets in real samples.  In a study by 
Heyduk et al. (2005), a fluorescence-based sensor was developed for the detection of thrombin in 
complex matrices using fluorescence resonance energy transfer (FRET) as the readout modality.  
Using aptamers that recognized two different epitopes on thrombin, each aptamer was designed 
attached via a long linker to a short complementary seven-base sequence to which a donor or 
acceptor dye was conjugated (see Figure 1.5).69  In the presence of the target, the aptamers bind 
to different epitopes on thrombin causing the dye-labeled complementary oligonucleotide 
sequences to anneal generating a FRET response.  Other biosensor formats have involved the 
interaction of aptamers developed against HIV-Tat and tubulin proteins with transduction 
accomplished via surface plasmon resonance, in which thiol functionalized aptamers were 
immobilized onto glass slides for capturing the target molecules.70, 71  
Microarrays consist of recognition probes covalently immobilized onto a solid support, 
such as glass. The recognition elements typically used for microarrays are oligonucleotide probes 
for targeting DNAs/RNAs, or antibodies, for targeting proteins. However, aptamers can be used 
for microarrays as well.  In a study to optimize the conditions for producing aptamer microarrays, 
biotin functionalized aptamers were used as capture elements on streptavidin-coated microarray 
glass slides.60, 72 
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Figure 1. 5 Schematic of the thrombin detecting aptamer beacon designed to produce a FRET 
signal when both aptamers bind to thrombin. (Adapted from Heyduk and Heyduk 2005)69 
 
Conditions for effectively generating the microarrays such as pH and buffer composition were 
considered. The researchers found that phosphate buffered saline containing 5 mM MgClB2B could 
be used in assays of different targets even though it was not the buffer used in the SELEX 
process for some of the aptamers.72 They also demonstrated that aptamer microarrays can be 
developed on streptavidin-coated glass slides using automated systems for the detection of 
labeled protein in cell lysate.60   
In the separation sciences aptamers have been used in affinity chromatography (AC),73 
affinity probe capillary electrophoresis (ACE), and capillary electrochromatography (CEC).13  In 
AC studies using aptamers in place of antibodies, a biotinylated aptamer of adenosine 
immobilized on streptavidin beads was used for the separation of adenosine from its analogues, 
cyclic-AMP, NAD+, AMP and ADP.  It was observed that the column could selectively retain 
and separate ATP and its analogs.74  CEC studies using immobilized thrombin aptamer were 
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carried out to separate non-target analytes such as binary mixtures of amino acids (D-
tryptophan/D-tyrosine and D and L-tryptophan) and polycyclic aromatic hydrocarbons.75  Most 
separation studies performed using aptamers have been ACE-based to determine the interaction 
of aptamers with their targets.  The ease of labeling aptamers during synthesis allows generation 
of fluorescently-tagged aptamers for detection of analytes of interest or for real-time monitoring 
of targets in clinical samples.76  In a competitive assay a fluorescently labeled DNA aptamer was 
used for quantifying human immunoglobulin E  by ACE.77  
The goal of this research was to demonstrate the attributes of aptamers in various 
bioanalytical assays using a polymer-based microfluidic format and to evaluate the 
immobilization of aptamers for affinity-based methods using polymeric substrates.  For example, 
in Chapter 2, the use of dye-labeled thrombin aptamers for the detection of thrombin in plasma 
by PMMA microchip capillary gel electrophoresis will be discussed.  Aptamers have been used 
in affinity-based sandwich assays for electrochemical detection in biosensors. In Chapter 4, I will 
discuss the application of aptamers in dual-aptamer sandwich assays on PMMA substrate using 
fluorescence detection. 
Recombinant DNA technology provides a means of producing relatively high amounts of 
low abundant biomarkers, such as membrane-bound proteins. This enables the creation of 
recombinant proteins in high purity and reasonable amounts that make them appropriate for the 
SELEX process to generate aptamers against these targets, which may serve as biomarkers for in 
vitro diagnostics. I will also show in this dissertation the cloning and expression of a 
hexahistidine tagged recombinant of the epithelial cell adhesion molecule (EpCAM), which is a 
membrane protein over-expressed in epithelial cells originating from adenocarcinomas.78  I will 
demonstrate in Chapter 3, an extensive technique toward the production of this membrane-bound 
recombinant and its purification to greater than 99% purity through the use of immobilized metal 
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affinity chromatography with electro elution. This purified recombinant protein can thus be used 
as a target for SELEX to generate aptamers against the native protein, which currently do not 
exist (see Table 1.1). 
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Chapter 2 Poly(Methyl Methacrylate) Microchip Affinity Capillary 
Gel Electrophoresis of Aptamer-Protein Complexes for the Analysis 
of Thrombin in Plasma* 
 
2.1 Introduction 
Thrombin is a multi-functional serine protease that plays procoagulation and anticoagulation 
roles in hemostasis.  As a procoagulant, thrombin activates factors V, VII and XI through a 
feedback mechanism and converts fibrinogen to fibrin during clot formation. P1, 2 P  Thrombin also 
regulates coagulation by binding to thrombomodulin to activate protein C.P2 P  Because of its 
importance in the maintenance of hemostatic balance, its level of generation in the blood can be 
greatly affected by the onset and progression of certain diseases. 
In diseases marked by hypocoagulation, such as hemophilia A and B, which are 
characterized by the generation of low levels of factors VIII and IX, respectively,P3 P clotting time 
is prolonged leading to excessive bleeding due to lower levels of generated thrombin.  The role 
of thrombin and prothrombin in proteolysis of microtubule associated tau protein in the brain has 
been studied as well and hypothesized to be important in the development of alzheimer’s disease 
and Parkinsonism dementia of Guam.P4 P  Hypercoagulation in thromboembolic diseases P5-10P, such 
as acute coronary syndromes in which intracoronary thrombus formation occurs in disrupted 
atherosclerotic plaque, is characterized by elevated levels of thrombin.  
The aforementioned conditions and the need for tight regulation and reporting on thrombin 
levels in plasma creates the need for monitoring thrombin using a simple, robust but highly 
sensitive assay. P11-13P These assays can also be used for determining the effectiveness of 
therapeutic treatments, such as administering therapeutic drugs for the treatment of hemophilia P14, 
15
P or the use of heparins as anticoagulants after surgery or in thromboembolic disease 
treatment.P16, 17P  
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Thrombin is responsible for its own non-linear generation, which occurs in two phases.  The 
first phase results in nanomolar (i.e., 10-30 nM) amounts of thrombin P18 P and represents the time 
within which clot formation occurs.P2P  The second phase, the propagation phase, occurs with 96% 
of thrombin generated and is usually overlooked in some techniques for determining disorders in 
hemostasis.  Average thrombin generation profiles reported for normal individuals show 
maximum thrombin levels between 200 nM and 800 nM. P12, 18P  
Current methods available for analyzing thrombin in blood include: Clotting-based assays P19 P, 
which depend on the time it takes for fibrin formation; monitoring enzymatic activity of 
generated thrombin using a synthetic chromogenic P20, 21 P or fluorogenic substrate; P22-24P 
immunoassays; P25, 26P or capillary electrophoresis (CE) of hydrolytic products of thrombin’s action 
on fibrinogen. P27P   In clotting-based techniques, the time required for clot formation to occur in a 
sample is determined and compared to a clotting standard curve generated using different 
concentrations of thrombin.  This technique addresses the initiation phase of thrombin generation 
since only 10 nM of thrombin is required for clot formation.  Although clotting-based techniques 
are useful in identifying congenital abnormalities associated with hemophilia A, B and C and for 
evaluation of oral anticoagulant therapies, they overlook the propagation phase of thrombin 
generation.P2, 5 P  The propagation phase provides information on the level of depression of 
thrombin generation and is most important in hemorrhagic syndromes.  
Immunoassays for thrombin include enzyme-linked immunosorbent assays (ELISA) and 
western blotting for detecting thrombin-antithrombin III complex, fibrinopeptide A, prothrombin 
and factors such as factor V and platelet factor 4.P22, 25P  These antibody-based assays are typically 
very time consuming requiring assay turn-around-times as long as 24 h or more. 
Thrombin assays based on enzymatic activity are very popular approaches for continuously 
monitoring the thrombin generation cycle using synthetic chromophore or fluorophore 
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conjugated oligopeptides  as performed in the endogenous thrombin potential (EPT) test.P15, 20, 24P  
This approach can be used in a microtitre plate format for large sample number processing and 
also with platelet-rich or poor samples through activation of coagulation by adding human 
replicated recombinant tissue factor in the presence of synthetic phospholipids.P9, 23 P  Chromogenic 
assays require the utilization of defibrinated plasma samples in the analysis due to increased 
interference from the resulting turbidity when fibrinogen is added to the assay.  Fluorogenic 
assays are more sensitive and allow for the use of smaller sample sizes compared to their 
chromogenic counterparts, however, there is no direct linear correlation between the 
fluorescence signal and thrombin activity.P28P  
Another technique for monitoring thrombin levels is capillary electrophoresis (CE) of 
fibrinopeptides with ultraviolet absorption detection.P27P  CE provides highly efficient separations 
of a wide range of analytes in short development times due to the ability to use high electric field 
strengths without degrading separation performance.  The capability of this technique to separate 
and simultaneously concentrate an analyte in a mixture for identification and quantification 
makes CE a valuable technique for the analysis of low levels of potential disease biomarkers. P29 P  
In addition, CE can be used for real-time sample analysis due to its short development times P30P.  
Various formats have been developed for CE including affinity capillary electrophoresis (ACE), 
which combines high affinity probes, such as antibodies or aptamers, with their respective 
binding partners.P31, 32P  ACE coupled to laser-induced fluorescenceP33 P detection enables the 
analysis of trace levels of analytes with high specificity.P34, 35P  
The affinity probe of choice for competitive and non-competitive formats of ACE separations 
has traditionally been antibodies due to their high specificity. P36P  In the competitive format, the 
antigen or antibody is incorporated into the running buffer to maintain complexes formed at 
equilibrium.  The non-competitive format, also known as non-equilibrium CE, is run without 
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addition of the affinity probe to the CE running buffer such that the equilibrium mixture of 
affinity probe and its target are analyzed under non-equilibrium conditions.P37, 38P  To permit LIF 
detection, the affinity probe can be fluorescently labeled to simplify the implementation of the 
assay.  Unfortunately, most labeling chemistries for antibody-based affinity probes lead to non-
uniformity in the number of dyes attached to the antibody,P36P with subsequent generation of 
multiple peaks during electrophoresis and difficulties with quantitation.  
The development of aptamers as potential affinity probes can eliminate the problem 
associated with multiple labeling due to the ease and uniformity of dye incorporation during 
solid phase synthesis of the aptamers. P31, 39P  Aptamers are synthetic single-stranded 
oligonucleotides, obtained using random nucleotide libraries through Systematic Evolution of 
Ligands by Exponential enrichment (SELEX), with high binding specificity for their cognizant 
targets.P40P  They are structurally more stable when compared to antibodies,P39 P making them 
attractive alternatives to antibody-based probes for ACE.  
Two DNA aptamers, HD1 and HD22, bind with high affinity to thrombin’s exosites I and II, 
respectively, and have been used in various applications for thrombin analysis.P40,41P  ACE 
utilizing aptamers as affinity probes have been carried out using conventional capillary zone 
electrophoresis, CZE,P42P for studying protein-DNA interactions and in some cases for quantifying 
this target.P42, 43 P  Thrombin and its interaction with anti-thrombin III was studied by ACE with 
real-time monitoring of protein-protein interactions using fluorescently labeled HD1 aptamer.P43 P  
In this study, protein-protein interactions were analyzed using CZE by adding polyethylene 
glycol (2%) to the running buffer in order to stabilize the aptamer-thrombin complex.  In another 
study, Berezovski et al.P38P analyzed thrombin-HD1 complexes by non-equilibrium CZE to 
determine binding constants and unknown thrombin concentrations using calculated dissociation 
constants and dissociated peak areas from the electropherograms.P38 P 
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Implementation of various CE formats in microfluidic devices have been proposed for a 
number of applications and offers some attractive attributes, such as simplicity in its 
implementation, short development times for the electrophoresis, integration of front-end sample 
processing steps to the separation platform and potential real-time analysis capabilities.  The use 
of polymers as the substrate material for microchip CE is particularly attractive due to the 
flexibility in the choice of micromanufacturing the devices, the ability to produce chips in a high 
production mode and at low-cost and the favorable optical properties of many polymeric material, 
such as poly(methyl methacrylate), PMMA.P44P  In our laboratory, work has been reported on the 
effective utilization of polymeric microchips for many types of bio-separations.P45P  
In this report, we will discuss the use of microchip electrophoresis using PMMA substrates 
for the high resolution and rapid analysis of thrombin in plasma.  Microchip CZE and microchip 
capillary gel electrophoresis P4 P were evaluated as possible modes to analyze thrombin using 
aptamers as affinity probes under non-equilibrium conditions.  Characterization of the 
electrophoretic properties of thrombin in the presence of its DNA aptamers, HD1 and HD22, that 
were fluorescently labeled were compared to select and optimize the separation best suited for 
ACE analysis in terms of separation speed, resolving power and electrophoretic reproducibility.  
2.2 Experimental 
2.2.1 Reagents and Materials 
Human alpha thrombin (MW=37,600 Da), thrombin inhibitor (FPRCK), prothrombin and 
human plasma were obtained from Haematologic Technologies Inc. (Essex Junction, VT).  
Poly(ethylene glycol), PEG, propionic acid disulfide was obtained from PolyPure (Oslo, 
Norway).  Alexa Fluor 633 maleimide fluorescent dye was obtained from Invitrogen (Carlsbad, 
CA).  Immobilized Tris (2-carboxyethyl) phosphine (TCEP) used in disulphide bond reduction 
was purchased from Pierce (Rockford, IA).  Acrylamide (99%), N, N, N’, N’-tetra-
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methylethylenediamine (TEMED) and ammonium persulfate (APS) for linear polyacrylamide 
(LPA) preparation and Micro Bio-Spin® 6 chromatography columns were obtained from BioRad 
Laboratories (Hercules, CA).  Alexa Fluor 647 labeled thrombin specific aptamers, HD1 and 
HD22, and unlabeled poly deoxythymidine (poly-dT), (5’Alexa 647 N/sp9/TTT GGT TGG TGT 
GGT TGG; 5’Alexa647 N/sp9/TAG TCC GTG GTA GGG CAG GTT GG GG TGA CT; and 
TTT TTT TTT TTT TTT TTT), were obtained from Integrated DNA Technologies (Coralville, 
IA).  Rabbit blood citrate (Colorado Serum Co., Denver, CA) was used as a plasma source.  
Methyl hydroxyl ethyl cellulose (MHEC), Tris(hydroxyamino) methane (Tris) and glycine were 
from Sigma-Aldrich (St. Louis, MO).  Nanopure water was obtained from a Barnstead Ultrapure 
water system (Barnstead/Thermolyne, Dubuque, IA) and was used in all buffer preparations and 
rinsing steps.  PMMA sheets (4 mm thickness for microchip substrate and 0.125 mm thick cover 
slips) were obtained from GoodFellow (Berwyn, PA).  
2.2.2 Thrombin Labeling Procedure 
Human alpha thrombin was site-specifically labeled with Alexa Fluor 633 using peptidyl 
chloromethyl ketone inhibitor (FPRCK) as follows: An 87.3 μL aliquot of a 546 μM PEG (n = 7) 
acid disulphide was added to 113.7 μL of 100 mM MES (pH 6.0) containing 10 mg/mL 1-ethyl-
3-[3-dimethylaminopropyl] carbodiimide, EDC, and 12 mg/mL N-hydroxysulfosuccinimide, 
NHS, and allowed to react for 15 min at room temperature.  The PEG succinimidyl ester 
disulfide mixture was reacted with 9.5 μmol of FPRCK for 1.5 h at room temperature.  A 30 μL 
aliquot of the crosslinker-inhibitor conjugate was treated with immobilized TCEP for 30 min to 
reduce the disulphide linkages and 200 μL containing 1 mg of Alexa Fluor 633 maleimide dye 
was added.  This was allowed to react for 2 h at room temperature with excess ethylene diamine 
(0.1 μL) added to terminate the reaction.  The dye-labeled inhibitor was filtered by centrifugation 
into a solution containing 1 mg of thrombin in HEPES buffer (pH 7.4).  This was allowed to 
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react overnight at 4°C with shaking.  Alexa Fluor 633-labeled thrombin was purified using 
desalting columns and analyzed by denaturing polyacrylamide gel electrophoresis.  Labeled-
thrombin used in the CE experiments was exchanged into the appropriate CE buffer using Micro 
Bio-Spin® 6 columns prior to the electrophoresis. 
Buffers used for the electrophoresis and aptamer assays contained Tris (25 mM) and Glycine 
(19 mM) as the major constituents and adjusted to the required ionic strength and pH.  Other 
components, such as methyl hydroxy ethylcellulose (MHEC) and LPA were added when needed.  
Linear polyacrylamides (LPAs) were synthesized by reacting 800 mg of acrylamide with 38 mg 
of APS and 12 μL TEMED in a total volume of 20 mL of Tris-Glycine (TG) buffer.  The 
reaction mixture was degassed by sonication for 10 min and incubated for 2 h at 60°C.  The LPA 
produced was precipitated with100% ethanol at 2.5 times its volume, centrifuged and the 
precipitate dried and re-suspended in twice its initial volume using a TG buffer. 
2.2.3 Optimization of Aptamer Assay Conditions  
Binding assays were prepared by incubating unlabeled thrombin with Alexa Fluor 647-
labeled HD1 or HD22 aptamers in a TG or other CE running buffer.  Incubation time was 1 h at 
room temperature but later reduced to 10 min when it was observed that binding saturation was 
achieved at the shorter incubation time.  Fixed concentrations of aptamer (500 nM) were 
incubated with thrombin ranging from 10 nM to 500 nM concentrations for the CE analyses.  
2.2.4 Microchip CE  
Microchip CE was performed in single channel “simple T” PMMA microfluidic devices with 
all separations performed at room temperature.  The devices were hot-embossed into 4 mm thick 
PMMA wafers using a micro-milled brass mold master.P46 P  All channels were 50 μm wide and 50 
μm deep.  A 10 mm injection cross was bisected 5 mm from one end of a 50 mm separation 
channel.  Holes of 2 mm diameter were drilled at the ends of the channels to provide reservoirs 
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for the separation buffer, sample and waste.  A 0.125 mm thick PMMA cover slip was thermally 
annealed to each embossed microchip at 107°C for 25 min after cleaning by sonication in 
detergent and nanopure water for 6 min followed by drying at 70°C for 30 min.  In each series of 
experiments, three different PMMA microchips were selected to test assay reproducibility. 
All buffers used for the microchip CE studies were filtered and degassed by sonication for 10 
min prior to use.  Microchip CZE (reverse mode – injection end cathodic and detection end 
anodic) of dye-labeled thrombin was performed using a 25 mM TG (pH 8.4) running buffer.  
Microchip CGE was accomplished with a TG buffer containing 0.01% MHEC (used to suppress 
the EOF and reduce non-specific adsorption) and LPA prepared with 2% acrylamide and 
buffered at pH 8.8.  The microchips were rinsed for 2 min with 0.2 M NaOH followed by a 
nanopure water rinse for the initial use of a microchip device.  For microchip CGE, the channel 
surfaces were pre-conditioned with 5 mg/mL MHEC in deionized water for 10 min and rinsed 
with TG buffer without LPA before filling the device with the CGE running buffer containing 
LPA.  Microchip CGE was carried out in a reverse mode of operation (injection end cathodic and 
detection end anodic).  
The electrophoresis equipment used in this work, consisting of four independently controlled 
high-voltage power supplies and a laser-induced fluorescence P33 P detection system, was assembled 
in-house and has been reported previously.P45P  Prior to injection, a positive voltage (0.2 kV) was 
applied to the sample reservoir for ~20 s while allowing the other three reservoirs to float.  
Sample was then injected by applying a positive voltage (0.3 kV) to the sample waste reservoir 
for the required length of time to allow sample to migrate into and fill the fixed volume injector.  
Separation was achieved by applying 1.5 kV to the separation waste reservoir (anode) and 
maintaining the sample and sample waste reservoirs at 11% and 10% of the applied voltage 
applied to the separation waste reservoir, respectively, and grounding the separation buffer 
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reservoir (cathode).  Detection was carried out 2.3 cm from the injection point (effective 
separation length, LBeff B= 2.3 cm) using LIF with an excitation wavelength of 632.8 nm supplied 
by a He-Neon laser. Individual samples of dye-labeled aptamers, HD1 and HD22, were diluted 
in the electrophoresis run buffer to a final concentration of 500 nM, while dye-labeled thrombin 
was buffer exchanged into TG buffer and diluted to 2 μM with either the microchip CZE or 
microchip CGE running buffer.  
2.2.5 Standard Curve Generation  
A fixed concentration of aptamer (500 nM) was pre-incubated with various concentrations of 
thrombin (10 – 500 nM) for 10 min at room temperature in the electrophoresis run buffer and 
analyzed by microchip CGE.  Electropherogram peak areas for data analysis were integrated 
using Microcal Origin software (OriginLab Corp., Northampton, MA).  The thrombin/aptamer 
complex electrophoretic peak areas were normalized by dividing the complex peak area by the 
combined peak areas of free aptamer and complex.  These values were used in plotting standard 
curves.  The equilibrium complex concentration at each thrombin level was obtained by 
multiplying the peak area fractions by the initial aptamer concentrations and plotted against the 
initial thrombin concentrations. 
2.2.6 Analysis of Plasma Samples  
Rabbit plasma was obtained by centrifuging citrated rabbit blood at 2500x for 20 min and 
decanting the plasma into clean tubes for storage at -20°C. Human and rabbit plasma, thawed 
and centrifuged, were diluted to 10, 25 and 50% in the electrophoresis run buffer and spiked with 
dye-labeled HD22 to a final concentration of 500 nM.  Each sample was incubated at room 
temperature for 10 min with the aptamer solution (500 nM) and analyzed by microchip CGE.  
Prior to assay preparation, the plasma was either used without pretreatment or buffer exchanged 
into TG buffer containing 0.01% w/v MHEC.  Later, unlabeled poly-dT was added to the diluted 
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plasma samples at a 3 μM final concentration to reduce non-specific interactions between dye-
labeled HD22 and plasma components. 
2.3 Results and Discussion 
2.3.1 Optimization of Aptamer Assay Conditions  
Various incubation times used for aptamer binding to thrombin in these non-equilibrium-
based assays were evaluated and ranged between 10 min to 1 h.  Metrics used to optimize the 
incubation time included the amount of complex formed and the resolution between the complex 
and free aptamer electrophoretic bands.  Formation of the G quartet structure is facilitated by the 
presence of potassium cations and has been reported to enhance binding of HD1 and HD22 
aptamers to thrombin.P47-49P  Addition of KCl salt up to 5 μM to the electrophoresis buffer resulted 
in a substantial increase in the current level, potentially leading to excessive Joule heating, which 
could affect electrophoresis performance in terms of plate numbers.  Thus, in this study the 
incubation of the aptamers with thrombin was carried out in the absence of KP+P ions.  The initial 
incubation time of aptamers with thrombin evaluated was 1 h and the electrophoretic peak area 
of the complex band was determined.  However, it was found that a 10 min incubation time was 
adequate to maximize the number of thrombin/aptamer complexes based on the electrophoretic 
peak area of the complex.  The average complex peak areas obtained for HD22 assays of 50 nM 
thrombin incubated at room temperature was 0.19 ± 0.03 for times ranging from 30 min to 1 h, 
while the 10 min incubation time gave an average peak area value of 0.20 ± 0.03.  
2.3.2 Microchip CZE  
Most CE-based affinity assays reported to-date using aptamers as the affinity probe have 
employed free-solution capillary electrophoresis.  There have been only a few reports in the 
literature using affinity capillary gel electrophoresis, P50-52P which can potentially provide higher 
resolution and efficiencies compared to CZE as well as stabilizing the aptamer/thrombin 
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complex when run under non-equilibrium conditions.  Thus, in this study we were interested in 
comparing the performance of microchip CZE and microchip CGE for the analysis of thrombin 
using PMMA microdevices with aptamers as the affinity probes.  
To understand the electrophoretic behavior of thrombin using PMMA as the electrophoresis 
substrate, dye-labeled thrombin was first analyzed by microchip CZE without the affinity probes.  
Figure 2.1a shows a representative electropherogram for the CZE/LIF analysis of dye-labeled 
thrombin only.  At pH 8.4, the dye-labeled thrombin possessed a migration time of ~5 min (LBeff B= 
2.5 cm).  Subsequent injections on the same device without pre-conditioning the separation 
channel resulted in no observable thrombin peak or a very broad peak appearing at ~1,000 s.  
The lack of reproducibility between CZE runs was most likely due to alterations in the 
electroosmotic flow (EOF) of the PMMA device due to adsorption artifacts. EOF determinations 
at pH 8.4 for unmodified PMMA devices and the electrophoretic mobility of the dye-labeled 
thrombin indicated that they were very similar in magnitude (see Table 2.1), thus leading to 
longer and irreproducible migration times for thrombin during microchip CZE, especially with 
slight changes in the magnitude of the EOF due to adsorption to the device wall. In fact, slight 
increases in the EOF can cause migration toward the cathode and as such, the thrombin would 
not be seen by the LIF detection point, which is located at the anodic end of the separation 
channel (reverse mode for electrophoresis). 
We also found that attempts to reduce EOF and adsorption by dynamically coat the PMMA 
separation channel using MHEC or covalently coating amine terminated polyethylene glycol 
through EDC coupling in ultraviolet light activated PMMA channels for CZE did not 
dramatically improve the migration time reproducibility for the dye-labeled thrombin (data not 




Figure 2. 1: Microchip CE traces of (A) Alexa Fluor 633-labeled thrombin run by microchip 
CZE in TG buffer at pH 8.4, E = 300 V/cm, and (B) HD1, HD22 and thrombin (all were labeled 
with Alexa Fluor 633) individually analyzed by microchip CGE in TG buffer (pH 8.8) with 2% 
LPA and E = 300 V/cm. Peaks appearing before the thrombin peak at less than 40 s in the CGE 
electropherogram were due to residual dye from purification of labeled thrombin. The detection 
was accomplished using laser induced fluorescence with a He-Neon laser (5 mW of laser power). 
For the microchip CGE case, the PMMA walls were conditioned with MHEC prior to the 
electrophoretic separation.  All separations were performed in PMMA chips. 
 
In order to provide better run-to-run reproducibility for the determination of thrombin, we 
investigated the use of microchip CGE since CGE analysis of proteins using low concentration 
sieving gels can provide high resolution and high migration time reproducibility. P53P  Thus, 
microchip CGE conditions were employed to reduce the detrimental effects of the EOF by 
incorporating MHEC to be used as a dynamic coating for the channel walls and LPA added to 
the run buffer to serve as a sieving matrix for the affinity complexes and the uncomplexed 
components in the sample matrix.  For the microchip CGE assays, LPA was prepared and diluted 
to about 2% total acrylamide.  
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Table 2.1: Microchip CGE and microchip CZE electrophoretic properties of thrombin, its 
aptamers and complexes formed in buffer or plasma. Symbols and abbreviations in this Table: 
Migration time, asymmetry factor (AF), resolution (Rs) and apparent electrophoretic mobility 
(μBappB) and electrophoretic mobility (μBep B). The negative sign on μBapp B, EOF or μBep B represents 




Figure 2.1b shows microchip CGE results of individually analyzed samples of fluorescently-
labeled thrombin and the two dye-labeled aptamers.  Addition of LPA to the buffer significantly 
enhanced the performance of the electrophoresis leading to highly reproducible migration times 
from repeated injections of the same sample loaded into the PMMA devices (RSD <10%, see 
Table 2.1).  The aptamers exhibited faster migration rates with apparent mobilities (μBapp B) of 2.67 
x 10 P-4 P and 2.82 x 10 P-4 P cmP2 P VP-1 P s P-1 P for HD1 and HD22, respectively, and higher plate numbers 
compared to thrombin (see Table 2.1).  Thrombin displayed a 10-fold increase in μBapp Bfor the 
microchip CGE format compared to microchip CZE due most likely to the diminished EOF 
value for the microchip CGE format. Peak asymmetry calculations P54P for individually analyzed 
thrombin and the aptamers showed peak tailing for thrombin and fronting for the 
 37
oligonucleotides, an indication that little interaction between aptamers and the channel walls 
occurred while thrombin adsorbed to some extent to the channels even after treatment with 
MHEC and addition of  LPA to the run buffer. 
Μicrochip CGE analysis of pre-incubated mixtures of the dye-labeled aptamers and 
unlabeled thrombin resulted in two well-resolved peaks, one for the free aptamer and the other 
for the thrombin/aptamer complex.  Figure 2.2 shows electropherograms obtained for three 
different thrombin concentration (75, 250 and 500 nM) incubated with 500 nM HD1 (A) or 
HD22 (B). The resulting electrophoresis profiles differ from the reported traces observed in non-
equilibrium CZE of aptamers and their targets, in which only a broad peak of the labeled aptamer 
was obtained due to complete dissociation of the complex during the electrophoresis. P38P  
The appearance of the complex peak for these non-equilibrium assays is a consequence 
of the presence of LPA in the electrophoresis run buffer, which provides a cage effect that can 
stabilize the protein/aptamer complexes during electrophoresis promoting re-association when in 
close proximity to dissociated aptamers and thrombin. P55-58 P  Also, because of smaller diffusion 
constants in gels compared to free-solution,P56, 57P dissociation may be greatly retarded during the 
short electrophoresis run times associated with the use of microchip CGE due to locally high 
relative concentrations of the ligands and target.  The peaks obtained for the microchip CGE 
analysis were also reproducible from run-to-run and between devices (see Figure 2.3).   
Resolution for the HD22 assay ranged from 3.0 to 1.6 with the resolution dependent upon the 
thrombin concentration with higher concentrations producing lower resolution between the 
complex peak and the free aptamer.  However, the complex peak remained well-resolved from 
the free HD22 peak even at the highest thrombin concentration investigated (see Figure 2.2B). 
The HD1-thrombin assays showed a similar trend as that of the HD22 assays. Resolution and 
plate numbers for both peaks decreased with increasing thrombin concentration. However, as the 
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thrombin concentration increased the free HD1 and complex peaks merged (Figure 2.2A) 
creating a region of dissociated complex as observed previously. P34 P   
 
Figure 2.2: Electrophoresis traces of mixtures of 75, 250 and 500 nM unlabeled thrombin 
incubated with Alexa Fluor 647 labeled (A) HD1 and (B) HD22 showing the corresponding 
increases in complex peak areas with increasing thrombin concentrations (top to bottom). The 
electrophoresis run buffer consisted of TG buffer at pH 8.8 with 2% LPA gel with the microchip 
CGE performed using a field strength of 300 V/cm. Electrophoresis conditions were similar to 
those described in Figure 2.1B. 
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This region between the peaks would complicate peak area calculations for the complex for 
generating a standard curve for thrombin.  Thus, HD22 was selected for determining the level of 
thrombin in real samples due to the fact that the free aptamer and complex peaks were well-
resolved irrespective of thrombin concentration.  The better resolution for the HD22 assays 
compared to HD1 is a direct result of the higher complex thermodynamic stability of the HD22 
aptamer to thrombin compared to HD1.  
To check the extent of variation in electrophoretic characteristics of aptamers and complex 
from run-to-run and device-to-device, three devices molded from the same batch of PMMA were 
compared. Migration times were reproducible with variation below 10% RSD from device-to-
device and run-to-run (Table 2.1).  It was also observed that the level of variation in the 
normalized peak area between runs and from device-to-device reduced with increasing thrombin 
concentration, especially above 150 nM for the HD22 assays.   
2.3.4 Standard Curve Generation 
To show the trend in amount of complex produced as the ratio of aptamer-to-thrombin was 
varied by increasing the thrombin concentration, normalized complex peak areas were plotted for 
different concentrations of unlabeled thrombin used in assays with HD1 and HD22 (see Figure 
2.3).  No complexes were observed for HD1 assays below 50 nM initial thrombin concentration, 
whereas complex peaks could be obtained for the HD22 assay down to 10 nM of thrombin.  
Results showed a linear increase in complex peak area formed with increasing thrombin 
concentration (see Figure 2.3) up to 150 nM for both the HD1 and HD22 assays (RP2 P = 0.990).  
The limit of detection, taken as the lowest thrombin concentration for which a complex peak was 
produced following electrophoresis, for the HD1 assay was 50 nM while that for HD22 assay 
was 10 nM.  The difference in detection limits reflects the difference in affinity constants of the 
aptamers for thrombin.   
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Figure 2.3: Variation of the amount of affinity complex produced with increasing unlabeled 
thrombin concentration for assays with HD1 (red circle plot) and HD22 (black square plot), both 
labeled with Alexa Fluor 647, in terms of  average normalized complex peak areas obtained for 
the analyses carried out using three different PMMA microchips. The assays were performed 
using PMMA microchip CGE with LIF detection.  
 
HD22 has a lower dissociation constant (KBDB = 0.5 nM) compared to HD1 with a reported 
dissociation constant (KBD) of 24 nM P41P.  Due to the higher stability of the HD22/thrombin 
complex and its more favorable electrophoretic performance compared to HD1, the remaining 
studies used HD22 as the affinity probe. 
2.3.5 Analysis of Plasma Samples  
Quantitation of analytes in real samples such as blood presents several problems, which 
are usually addressed with different sample preparation techniques.  Whole blood consists of 
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different components with diverse solubility properties that can affect the analytical method of 
choice.  The ionic strength of blood can increase Joule heating during electrophoresis, while the 
presence of cells, carrier proteins such as albumin, and lipoproteins lead to increased protein 
adsorption to the separation channel walls.  To overcome some of these obstacles, plasma can be 
used for these assays.  Prothrombin, the inactive form of thrombin, is present in circulating blood.  
To evaluate the potential of prothrombin interference in plasma giving rise to false positive 
results, 100 nM prothrombin was pre-incubated with HD22 in the electrophoresis run buffer and 
was analyzed by microchip CGE.  We observed no complex peak using microchip CGE (see 
Figure 2.4A) indicating that the affinity probe would not bind to prothrombin. Assay conditions 
were optimized using plasma from citrate treated rabbit blood. The plasma samples were tested 
at 10, 25 and 50% v/v in the electrophroesis run buffer.  After removal of excess salt by 
transferring the protein components into TG buffer using Microbio-Spin® 6 columns, microchip 
CGE analysis was carried out with LIF detection.  Plasma treated only by diluting in the 
electrophoresis buffer produced an increase in current above 50 μA even at 10% dilution due to a 
higher sample ionic strength.  After exchanging the plasma into TG buffer, the main problem 
faced was adsorption of protein to the channel walls and association of the labeled aptamer with 
carrier proteins in the sample. This caused an increase in background fluorescence resulting in no 
electrophoretic peak for the thrombin/HD22 complex. 
Studies carried out on aptamers have reported the use of excess non-specific 
oligonucleotides as competitors to enhance aptamer selectivity. P59P This technique was thus 
employed in an attempt to minimized non-specific interaction between plasma components and 
HD22.  Unlabeled poly-dT at 3 μM was added to the plasma prior to adding the HD22 reagent. 
This allowed formation of a free aptamer peak and a complex peak during electrophoresis (see 
Figures 2.4B, C and D).  The plasma samples were again tested at 10, 25 and 50% levels.  The 
 42
10% plasma dilution enabled repeated injections of the same sample load while 25% plasma 
dilution could only be injected once after which the microchip had to be thoroughly cleaned due 
to highly irreproducible electrophoretic results.  Electropherograms could not be generated for a 
50% plasma sample due to increased current and poor peak shape and in some cases, the absence 
of the target complex peak.  A slight shift in the migration time of the HD22/thrombin complex 
occurred for the plasma samples compared to the control samples most likely due to interaction 
of thrombin with components of hemolized blood.   
 
 
Figure 2. 4: Representative microchip CGE traces for HD22 assays in TG buffer (pH 8.8 E = 
300V/ cm) for (A) 100 nM prothrombin analysis in buffer and (B) 25% rabbit plasma, (C) 10% 
and (D) 25% human plasma samples. Plasma samples were desalted and buffer exchanged into 
CGE buffer without LPA prior to dilution and microchip CGE analysis. 
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Based on the results obtained from rabbit plasma, human plasma was also analyzed for the 
presence of thrombin using affinity microchip CGE and the HD22 aptamer affinity probe. Ten 
and 25% dilutions of buffer exchanged plasma were analyzed with 500 nM HD22 (see Figures 
4C and 4D).  Microchip CGE results indicated the presence of thrombin at an average 
concentration of 543 ± 81.5 nM (see Table 2.1). This falls within the generated thrombin 
concentration range found in the literature. P12 P  The time required for sample preparation and 
analysis by this microchip CGE technique was relatively short (approximately 14 min for sample 
preparation and 2 min for microchip CGE).  
2.4 Conclusion 
We have demonstrated the use of PMMA microfluidic devices for conducting rapid affinity 
microchip CGE of a target protein using aptamers as the affinity probes with an electrophoresis 
development time of <2 min. For these microchip CGE assays, non-equilibrium conditions were 
used to allow for the sensitive LIF detection of thrombin without requiring fluorescence labeling 
of the target.  Migration times were reproducible for thrombin complexes and free aptamers in 
CGE buffer with device-to-device RSD variations below 10%. By removing salts from plasma 
and adding an unlabeled random sequence oligonucleotide to the plasma, thrombin was detected 
in rabbit and human plasma. This method can be easily adapted for high throughput screening of 
plasma samples in a polymeric microchip device designed with multiple channels for analyzing 
several samples in parallel. Work is currently underway in our lab to develop detection systems 
for use with high throughput polymeric microchips for use with assays requiring high throughput 
screening capabilities. 
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Chapter 3. Investigating the Expression of Recombinant EpCAM in 
Bacteria and Mammalian Cells and the Development of a Selective 
Tandem IMAC/ Electro Elution Purification Protocol for Histidine-
Tagged Recombinant Proteins in Mammalian Cells 
 
3.1 Introduction  
Affinity-based bioanalytical techniques play a pivotal role in disease diagnosis and 
prognosis due to the high target specificity and selectivity afforded by the affinity agents used in 
these methods. Forty percent of eukaryotic cell proteins, which often times are used as 
biomarkers in diagnostic assays, are membrane-bound. These proteins can also serve as effective 
targets for drug development and antibody generation in disease treatment and diagnosis.1  
However, the need exists for obtaining the target proteins in a highly abundant and purified form 
in their native states to ensure recognition of the native target in complex environments by the 
affinity agent when used for affinity probe selection or designing and testing the biomolecular 
assay. 
In many affinity-based techniques, the common and commercially available molecular 
recognition element used has been antibodies either monoclonal or polyclonal.2  Recently, 
alternative recognition probes are becoming popular, such as aptamers or peptoids due to their 
ease of synthetic production, favorable chemical stabilities and good biochemical 
compatibilities.3-5 Unfortunately, few aptamer/peptoid probes are available for the large number 
of molecular/cellular targets used in many diagnostic assays.6  Therefore, to expand the library of 
aptamer/peptoid probes available for molecular recognition, large amounts of high purified target 
surrogates will be required for probe selection.  
Recombinant DNA technology (RDT) allows for the production of protein targets through 
manipulation of the complementary deoxyribonucleic acid (cDNA) generated from the proteins 
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of interest through, for example, incorporation of fusion tags to meet protein production and 
purification requirements of researchers.7, 8   
Recombinant protein expression consists of three components: a gene of interest, a vector 
for gene transfer into the appropriate host and  the host for protein expression.9  Figure 3.1 shows 
a schematic of the cloning and expression process.   
 
Figure 3.1 A schematic of the molecular cloning process. RNA extracted from an over-
expressing source of the protein biomarker is reverse transcribed to the cDNA of the target.  
After PCR amplification the cDNA insert is enzymatically incorporated into the vector with 
subsequent transformation of bateria with the recombinant vector. The recombinant vector 
containing the gene of interest is amplified by culturing the transformed bacteria in the presence 
of antibiotic and purified for transfection of eukaryotic hosts or transformation of bacteria for 
protein expression. 
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Starting with RNA extracted from a source that over-expresses the protein of interest, reverse-
transcription is performed to obtain the cDNA.  The cDNA thus obtained is amplified by 
polymerase chain reaction (PCR) and ligated into a vector, such as a plasmid.  The recombinant 
plasmid is amplified in bacteria by inducing uptake of the plasmid by the bacteria strain of 
choice, a process referred to as transformation.  The transformed bacteria is cultured in the 
presence of an antibiotic to which a resistance gene exists in the vector to enable selective 
growth of only bacterial cells containing the recombinant plasmid.  The amplified plasmid is 
purified and used in the transfection of eukaryotic hosts or bacteria transformation for protein 
expression (see Figure 3.1).10   
A wide variety of vectors are available for rapid and high throughput cloning of protein 
biomarkers in prokaryotic, eukaryotic and cell-free systems.11  Integral membrane proteins 
(IMPs) are physiologically responsible for interfacing extracellular biochemical activities with 
intracellular ones.12  They are implicated in various diseases and thus, approximately 50% of all 
drug targets are G-protein coupled receptors. 12-14  However, a major setback to structural 
determination studies on eukaryotic IMPs is the expression and purification of sufficient amounts 
of homogeneous protein. The complexity of eukaryotic IMPs presents problems with their 
expression in prokaryotic systems.14  Thus, most eukaryotic IMP recombinants are expressed in 
eukaryotes, such as insect and mammalian hosts in spite of the lower yields.13  Currently, 
approximately 60-70% of all recombinant protein pharmaceuticals are produced in mammalian 
cells, the most commonly used being the Chinese hamster ovary cells, due to the possession of 
organelles that allow post translational modification of proteins to generate them in their native 
conformations.7, 15, 16   
An important aspect of recombinant protein production requiring detailed planning to 
ensure very high levels of yield and purity while maintaining the protein’s structural properties is 
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the purification process.  To this end affinity purification techniques involving the use of 
antibodies or other affinity agents play a very important role in recombinant protein production.  
A widely used affinity method is the immobilized metal affinity chromatographic (IMAC) 
technique for purification of histidine tagged recombinant proteins from cell lysates and growth 
media either in conjunction with other purification methods or as a one-step procedure with 
protein yields >95%.17-21   
Unfortunately, eukaryotic cells have higher contents of cysteine and histidine compared to 
prokaryotes which bind to metal ions when exposed in clusters on protein surfaces under native 
conditions.22, 23 This leads to interference with IMAC purification of recombinant proteins from 
the expression hosts.  Thus, to ensure high levels of protein purity, the IMAC technique can be 
used in conjunction with other purification techniques to remove co-eluting impurities.  
Electrophoresis has become an invaluable tool for protein analysis and purification.24  An 
electrophoretic method commonly employed as an extraction technique for isolating protein 
bands from electrophoresis gels is electro elution. This purification and extraction method 
enables researchers to obtain highly purified biomolecules, such as proteins, in native form with 
yields ranging between 80 - 100%.24  Electro elution, carried out either in static or continuous 
mode, has proven useful in the recovery of recombinant proteins from cell lysates. The technique 
has been employed in the continuous format for single-step purification of recombinant proteins 
from bacterial expression systems and inclusion bodies.25-27 Electro elution has also been used as 
a second purification step in, for example, the purification of tristetraprolin from an enzyme 
digest of an affinity purified recombinant fusion protein.28 
By coupling affinity chromatography with electro elution, electrophoretically pure 
histidine-tagged recombinant proteins expressed in eukaryotic systems may be obtained in native 
conformation for further downstream processes.29  The technique is also adaptable to 
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microfluidic systems for simultaneous and high throughput processing of several protein 
biomarkers due to the ease of miniaturization of electrophoretic processes and chemical 
modification of polymeric substrates for immobilization purposes.1 
To study the cloning and expression characteristics in various expression systems and to 
develop a purification protocol for laboratory-scale production of integral membrane proteins, 
we chose the epithelial cell adhesion molecule (EpCAM), a 40 kilodalton transmembrane protein 
over expressed in breast cancer and other carcinomas, as our model.30, 31  In this study we cloned 
EpCAM as a hexahistidine-tagged fusion protein in two different vectors for expression in 
mammalian and bacterial cells to optimize its expression for purification.  A purification protocol 
based on tandem IMAC with electrophoresis and electro elution to obtain a pure and correctly 
folded protein as determined by western blot and sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) was developed. 
3.2 Experimental 
3.2.1 Cell Lines  
Breast carcinoma cell  lines MCF7 (HTB), Hs578T  used for total RNA extraction and 
western blots of EpCAM,  baby hamster kidney (BHK) cell line, cervical cancer cell line (Hep2), 
and Cos 7 cell line used in cloning and expression of recombinant EpCAM were obtained from 
the American Type Culture Collection (Manassas, VA). Cells were stored in liquid nitrogen and 
at – 80 °C until required. 
3.2.2 Reagents and Materials 
Cloning reagents and kits include Novagen UltraMobius plasmid kits (EMD Bioscience, 
San Diego, CA), Qiagen RNA/DNA mini kit (Hilden, Germany), lipofectamine and mammalian 
expression vectors obtained from Invitrogen Corp.(Carlbad, CA) were pEF6/V5-His TOPO TAP® P 
and pcDNA 3.1 (+).  EpCAM specific primers (Forward: 5’-AGC ATG GCT CCC CCG CAG 
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GTC C-3’ (bases 176-197); Reverse : 5’- GGC GTT GAG TTC CCT ATG CAT CTC AC CAT-
3’ (bases 1091-1116)) flanking the region including the signaling peptide through part of the 
cytoplasmic region used for polymerase chain reaction (PCR) amplification of EpCAM cDNA 
were synthesized by Integrated DNA Technologies (Coralville, IA) based on the messenger 
RNA sequence of the tumor associated calcium signal transducer (TACSTD1: NM_002354) 
obtained from the National Center for Biotechnology Information (NCBI) website.  Restriction 
endonucleases and Quick Ligation kit used in the cloning process were obtained from New 
England Biolabs Inc. (Ipswich, MA).  Criterion Tris-HCl gels and electrophoresis and western 
blotting buffers were obtained from BioRad Laboratories (Hercules, CA).   
TalonP®P metal affinity resin used in affinity purification of recombinant EpCAM was 
obtained from ClonTech Laboratories Inc. (Mountain View, CA). FluoStar Optima microtiter 
plate reader (BMG LabTech, Durham, NC) was used for total protein determination by 
Biccinchonninic assay (BCA) (Pierce, Rockford, IL) and DNA quantitation by Cyquant cell 
proliferation assay (Invitrogen, Carlbad, CA).  Western blot reagents and antibodies utilized 
included Full Range Rainbow Protein marker, ECL Plus western blotting reagent (GE Healthcare, 
Piscataway, NJ), MagicMark XP western protein marker, anti-V5 , C-terminus anti-Histidine 
monoclonal (Invitrogen, Carlbad, CA), anti-hEpCAM (R&D, Systems, Minneapolis, MN) and 
anti-EpCAM VU D9 clone (EMD Biosciences, Inc., La Jolla, CA) primary antibodies. 
Detergents used in cell solubilization studies include dodecyl-β-D-maltoside (DDM) and sodium 
deoxycholate (DOC) from Sigma-Aldrich (St. Louis,MO), nonidet P40 (NP40) and n-octyl-β-D-
glucopyranoside (OβDG) from EMD Biosciences (La Jolla, CA).  Sodium molybdate used in 
NP40 buffer preparations and imidazole used in the purification studies were obtained from 
Sigma-Aldrich (St. Louis, MO). 
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3.2.3 Production of EpCAM cDNA from Total RNA of Breast Cancer Cells and Generation of 
EpCAM/Vector Constructs 
MCF7 and Hs578T breast cancer cells were cultured in Dubelco minimum essential 
medium (DMEM)  in p60 culture dished under 6% COB2 B at 37°C until the cells reached 
approximately 90% confluency. The adhered cells were first washed with sterile phosphate 
buffered saline (PBS) and solubilized with 1% SDS solution. After shearing the DNA and 
centrifuging to remove debris, the total protein contents of the lysates were determined by 
bicinconninic acid assay (BCA).  Aliquots of lysate containing 50 ug of total protein were 
analyzed by western blot to determine which cell line produced the highest level of EpCAM.  
MCF7 cells were cultured to 90% confluence and the cells harvested for total RNA extraction 
following the instructions for the Qiagen RNA/DNA kit. Total RNA was reverse transcribed 
using poly-dT primers to provide cDNA from which EpCAM cDNA was PCR amplified with 
EpCAM specific primers for cloning. The PCR amplification temperature cycle involved a 3 min 
initial denaturation at 95 °C followed by a 25 round thermal cycle of 30 s at 95 °C, 1 min at 
58 °C and 1 min at 72 °C.  A final extension at 72 °C for 7 min was carried out prior to cooling 
the PCR reaction to 4 °C. 
To generate histidine tagged EpCAM cDNA containing vectors for transformation and 
transfection, EpCAM cDNA obtained from RNA of MCF7 cells was first cloned into the 
pEF6/V5-His TOPO TAP®P mammalian expression vector for bacteria transformation as follows; 
PCR amplified EpCAM cDNA was added to the TOPO vector without prior purification and 
allowed to incubate for 5 min at room temperature. Competent E coli cells were transformed 
with the recombinant TOPO/EpCAM plasmid and cultured on Luria broth (LB) agar with 50 
ug/mL ampicillin overnight at 37 °C following the TOPO kit protocol.  The transformed E. coli 
cells were tested for the presence of EpCAM cDNA by PCR of heat lysed cells using EpCAM-
specific primers. Colonies which tested positive for EpCAM cDNA were cultured in Luria broth 
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(LB) containing 50 μg/mL ampicillin at 37 °C for 16 h. Purified recombinant plasmid was 
obtained using the UltraMobius plasmid extraction kit and analyzed by restriction enzyme digest 
to determine the correct insertion of EpCAM cDNA into the vector based on the DNA fragment 
sizes obtained.  Large scale plasmid preparation was carried out to obtain purified recombinant 
TOPO plasmid for extraction of EpCAM-V5-HisB6 B DNA sequence. 
Transfer of EpCAM-V5-HisB6 B cDNA from the TOPO/EpCAM plasmid to pcDNA 3.1 (+) 
vector was achieved by digestion of the TOPO/EpCAM plasmid with Kpn1 and EcoRV 
restriction endonucleases and digestion of pcDNA 3.1 (+) with Kpn1 and Pme1 enzymes.  The 
digested insert and vector DNA were agarose gel purified and extracted using the Novagen 
UltraMobius mini plasmid prep kit. The insert and plasmid DNA were then quantified and 
combined in a molar ratio of 3:1 insert to plasmid.  Using the Quick ligase kit, a 5 min ligation of 
the EpCAM-V5-HisB6 B insert into pcDNA 3.1 (+) was carried out to generate the pcDNA/EpCAM-
V5-HisB6 B recombinant plasmid. Transformed bacteria colonies containing this plasmid were 
selected on LB ampicillin (LB-amp) agar and determined to contain EpCAM cDNA by PCR. 
The transformed bacteria were cultured for plasmid preparation and storage at -80 °C in 10% 
glycerol.  Recombinant plasmid for bacterial expression of recombinant EpCAM (rEpCAM) was 
prepared by digestion of pTriEX-4 Neo vector with Xho 1 and Eco RV and sequential digestion 
of pcDNA/EpCAM-V5-HisB6 B with Xho 1 followed by Pme 1. The purified cut vector and insert 
were ligated as previously described and transformed in bacteria for amplification. 
All three recombinant plasmids were analyzed by restriction enzyme digest to determine 
the orientation of the insert in the vector. Fragments obtained were separated on 1% agarose and 
the sizes compared to the calculated fragment sizes. TOPO/EpCAM and pcDNA/EpCAM-V5-
His B6B were sequenced using EpCAM, T7 and BGH primers to verify correct sequence orientation 
and the absence of mutations in the EpCAM cDNA. 
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3.2.4 Bacteria Expression of rEpCAM 
pTriEx-4/EpCAM transformed Tuner (DE3) pLacI cells cultured in LB medium 
containing75 μg/ mL carbenicillin, 34 μg/ mL chloramphenicol and 1% glucose overnight at 
37 °C served as a starter culture for seeding fresh medium.  The cells were allowed to grow for 3 
h to an optical density (OD) between 0.5 and 1.0, measured at 600nm wavelength.  Protein 
expression was induced with different IPTG concentrations ranging from 0 to 1 mM and the 
cultures incubated for 2.5 h.  Aliquots of 1.5 mL cell suspension were centrifuges at 12, 0000 x g 
for 5 min and the cell pellets washed three times with phosphate buffered saline (PBS) before 
being lysed in reducing Laemli buffer and heat denatured for electrophoresis and western blot 
analysis.  OD measurements were obtained at various time intervals for EpCAM transformed 
tuner cells and control tuner cells cultured without IPTG to determine the growth pattern of the 
cells and for cultures before and after IPTG induction. 
3.2.5 Expression of C-Terminus Histidine-Tagged Recombinant EpCAM in Mammalian Cells 
Three mammalian cell lines BHK, Hep 2 and Cos 7 were transfected with 
pcDNA/EpCAM for mammalian expression of rEpCAM. The cells were grown to approximately 
90 % confluence, rinsed with PBS to remove growth medium and treated for 30 min with a 
suspension of lipofectamine emulsified recombinant vector in growth medium.  The transfected 
cells were cultured in the presence of 400ug/ mL G418 selection agent over a two week time 
period to create a rEpCAM expressing stable cell line. Cells were harvested every five days after 
transfection to test for the presence of rEpCAM by western blot using anti-EpCAM, anti-
histidine or anti-V5 primary antibodies. 
3.2.6 Purification of Recombinant EpCAM 
EpCAM expressing BHK cells were used in determining the best detergent for cell 
solubilization. Mild detergents DDM, DOC, NP40 and OβDG were selected and compared to 
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SDS to obtain the most effective non-denaturing detergent in terms of protein content. Cells in 
p10 plates were cultured under antibiotic selection until 90% confluency at 37 °C. The cells were 
rinsed with cold sterile tris buffered saline (TBS) and treated with 500 μL each of TBS 
containing different detergents and protease inhibitor cocktail. The cells were scraped and 
solubilized by several passes through 25 gauge syringes. The crude lysates were centrifuged for 
10 min at maximum speed in a microcentrifuge to separate insoluble cell debris from the 
supernatant. Cell pellets were solubilized in 1% SDS in TBS and total protein contents of both 
fractions were determined spectrophotometrical using the BCA method for total protein.  Lysate 
aliquots containing 50 μg total protein, were loaded on Criterion 10% tris-HCl gels and 
electrophoresed at 100 V for 2.5 h.  The resolved proteins were electro-transferred to 
nitrocellulose membrane at 100 V for 60 min in tris-glycine buffer for western blot analysis. 
Nonidet P40 detergent was selected for cell solubilization and added to Tris saline buffer at 
0.09% with 10 mM sodium molobdate.  
3.2.7 Optimization of mMetal Affinity Purification Protocol for Recombinant EpCAM 
Clarified cell lysate containing the recombinant protein was incubated with Talon® resin 
at a ratio of 1:5 resin-to-lysate volume for 2 h at room temperature or overnight at 4 °C on a 
shaker. Subsequent incubations were performed overnight at 4 °C, since this condition allowed 
maximum binding of protein to the resin. Bound protein was then washed with 10 column 
volumes of buffer containing different imidazole concentrations ranging from 1 mM to 50 mM to 
determine the most appropriate imidazole levels which would allow removal of non-specifically 
bound proteins while retaining the bulk of the recombinant protein on the resin.  Other additives 
such as 5% glycerol, sodium chloride (500 mM) and beta mercapto-ethanol (BME) (10 mM) 
were introduced in the binding and washing stages for protein stability and to determine their 
effectiveness in reducing the level of non-specifically bound proteins. Each wash step was 
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carried out in triplicate with 3 min room temperature incubation periods on a shaker and the 
buffer removed by centrifugation for 2 min.  The purified recombinant protein was eluted from 
the resin with one column volume of buffer containing imidazole at concentrations between 75- 
500 mM or EDTA (100 mM) and the eluted resin treated with 1% SDS solution to check the 
effectiveness of the elution buffer during the purification optimization process.  Imidazole at 500 
mM concentration was selected for elution of bound protein during the scale-up process.  IMAC 
fractions were analyzed by SDS PAGE and western blot to ascertain which fractions contained 
the recombinant EpCAM and the level of its purity.  Fractions collected were loaded on 10% 
polyacrylamide gel in volumetric ratios to allow comparison of the rEpCAM levels in each 
fraction. 
3.2.8 Gel Electrophoresis and Western Blot Analysis 
Samples of lysate and purification fractions were loaded on 10% polyacrilmide gels and 
electrophoresed at 100V for 2.5 h.  The separated proteins were electro-transferred to 
nitrocellulose membrane (BioRad laboratories, Hercules, CA) after which the membrane was 
washed and blocked  for 1 h with 5% skim milk in PBS buffer containing 0.05% Tween 20 
(PBS-T).  The membrane was incubated overnight at 4°C with anti-EpCAM antibody in 5% 
skim milk in PBS-T, washed 3 times with PBS-T for 5 min each and incubated 1 h at room 
temperature with horse radish peroxidase (HRP) linked secondary antibody.  The membrane was 
washed 3 times with PBS-T and ECL Plus western blotting chemiluminescence detection reagent 
added for 5 min.  Presence of rEpCAM was determined by exposure of the membrane to 
photographic film. 
3.2.9 Electro Elution of rEpCAM from SDS-PAGE Gels 
Pre-concentration of IMAC purified protein eluates was carried out by centrifugal 
ultrafiltration using centricon devices with molecular weight cut-offs (MWC) of 50, 30 and 10 
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kilodaltons (kD) and, in later experiments, by dialysis using MWC 20 kD slide-a-lyzer cassettes 
and concentrating solution.  The rEpCAM concentrates were electrophoresed on 10 % Criterion 
Tris-HCl gels to separate the target protein from co-eluting proteins.  The gels were stained with 
E-Zinc reversible stain (Pierce, Rockford, IL) and the rEpCAM bands excised and destained with 
tris/glycine buffer. The protein was electro eluted from the gel in a Model 422 Electro Eluter 
(BioRad Laboratories, Hercules, California) for 5 h in tris/glycine buffer with 0.05% SDS. The 
extracted protein was removed and concentrated by centrifugal ultrafiltration and analyzed by 
SDS-PAGE and western blotting. 
3.3 Results and Discussion 
In this study, two breast cancer cell lines (MCF 7 and Hs578T) were selected as sources 
for EpCAM due to over-expression of this biomarker in these cell types.  The cells were cultured 
and the total protein content determined followed by western blot analysis to determine the 
relative EpCAM expression level in each cell type.  Results showed a higher level of the target 
protein generated in the MCF 7 cells compared to the Hs578T cell line due to a faster growth rate.  
Thus the MCF 7 cell line was our source for total RNA extraction for the cloning process.  Total 
RNA was converted to cDNA from which the EpCAM cDNA was obtained for further cloning 
steps. 
3.3.1 Insertion of RT-PCR Amplified EpCAM cDNA into the Vectors 
PCR amplification of EpCAM cDNA carried out with primers flanking regions of the 
EpCAM cDNA from bases 176 to 1116 yielded a sequence greater than 900 bp in size on 1% 
agarose gel, which corresponds to the expected 941 bp cDNA size calculated using the EpCAM 
mRNA sequence (Locus: NM_002354) obtained from the NCBI website.  This portion of the 
EpCAm sequence encompasses the regions of the protein starting from the signaling peptide 
through most of the cytoplasmic domain.  The amplified sequence was immediately inserted into 
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the pEF6/V5-His TOPO plasmid without the need for prior purification of the pcr product.  
Results of cloning and sub-cloning EpCAM cDNA into TOPO, pcDNA 3.1 (+) and pTriEx-4 
Neo vectors are shown in figure 3.2. Recombinant plasmids generated for EpCAM expression 
were restriction enzyme digested and analyzed by agarose gel electrophoresis.  Fragments sizes 
were compared to calculated fragments expected for correctly inserted cDNA fragments (Figure 
3.2).  PCR amplification of recombinant plasmids from transformed bacteria using EpCAM 
primers indicated the presence of a 941 bp EpCAM sequence.   
 
Figure 3. 2 Agarose gel electrophoresis of restriction enzyme digests of the three recombinant 
plasmids produced for rEpCAM expression. Given below the image are the calculated fragment 
sizes expected for each restriction enzyme digestion. 
 
The TOPO TA cloning system was selected for cloning EpCAM cDNA due to the ease of 
cloning and the unidirectional TA cloning property of this technique, which prevented anti-sense 
orientation of the cDNA into the plasmid.  Also, the technique allowed cloning of PCR amplified 
 61
cDNA without prior purification of the cDNA from the PCR mixture, thus reducing the number 
of steps involved in the cloning process while still providing high cloning efficiency.  The 
pEF6/V5-His TOPO plasmid also iattached carboxy-terminus (C-terminus) hexahistidine and V5 
epitope tags on the recombinant protein, thus enabling purification of the protein by immobilized 
metal affinity chromatography and western blot detection of the recombinant protein using anti-
histidine antibody or anti-V5 antibody.  This property was exploited during transfer of the target 
cDNa into other plasmids.   
Fifteen colonies of pEF6/V5-His TOPO/EpCAM (TOPO/EpCAM) transformed E. coli 
bacteria were positive for EpCAM when analyzed by PCR.  Four colonies were selected, 
cultured and the recombinant plasmids purified and subjected to restriction endonuclease 
digestion using BamH1 and Mlu1 enzymes (see Figure 3.2).  Each enzyme produced three 
fragments analyzed by agarose gel electrophoresis, the sizes of which were compared and 
corresponded to the calculated fragment sized expected for a correctly inserted EpCAM cDNA.  
The pcDNA 3.1 (+) vector was selected for episomal expression studies based on its 
restriction enzyme map in order to allow transfer of the recombinant EpCAM-V5-HisB6 B 
(rEpCAM) cDNA from the TOPO/EpCAM plasmid.  The plasmid contains a SV40 gene for 
episomal expression in cells expressing the SV40 large T antigen.  The pTriEx-4 Neo vector was 
created for expression of target proteins in multiple systems including bacteria, insects and 
mammalian systems and was selected for bacterial expression of the rEpCAM protein. 
To ensure unidirectional orientation of the histidine and V5 tagged rEpCAM cDNA sub-cloned 
into pcDNA 3.1 (+) and pTriEx-4 Neo vectors, restriction maps of the vectors and EpCAM 
cDNA were compared and restriction endonuclease enzymes selected to generate an overhang 
and a blunt end each on the insert and vectors.  Thus, using Kpn1 and Pme1 on the TOPO 
recombinant and Kpn1 and EcoR V on pcDNA 3.1 (+), ligation of the excised histidine-tagged 
 62
EpCAM cDNA insert into  the pcDNA episomal vector was carried out to generate the 
pcDNA/EpCAM-V5-HisB6 B recombinant plasmid.  This procedure was repeated for the pTriEx 4 
neo vector used for bacterial expression of recombinant EpCAM.  The pcDNA/EpCAM-V5-HisB6 B 
plasmid was restriction enzyme double digested with Xho I and Pme I to obtain the histidine-
tagged rEpCAM and ligated into pTriex 4 Neo treated with  Xho I and EcoR V.  The resulting 
recombinant vectors showed correct orientation of the insert as determined by restriction enzyme 
digestion (see Figure 3.2).  To further confirm orientation without mutations the plasmids were 
sequenced with T7, BGH and EpCAM primers and compared to the GenBank sequence for 
EpCAM using the blast software. The sequence was at least 99% homologous to the EpCAM 
sequence and had no mutations.  Thus, large-scale plasmid amplification and purification were 
carried out for mammalian cell transfection and transformation of bacteria Tuner cells for 
expression studies.  Based on the DNA sequence for the recombinant, the molecular weight of 
the unglycosylated recombinant protein was determined to be approximately 37.033 kD.   
3.3.2 Bacterial Expression Studies 
Bacteria cells, Novagen Tuner(DE3)pLacI cells (EMD Bioscience,Inc., La Jolla, CA) 
transformed with pTriEx 4 Neo/EpCAM plasmid were cultured overnight and sub-cultured for 3 
hr at 37 °C prior to induction with various IPTG concentrations.  Induced cells were incubated at 
37 °C for 2.5 h and cell density measurements were obtained at 600 nm absorbance.  The results 
of bacterial expressions studies are shown in Figures 3.3-3.5.  The OD measurements of the 
growth of control and pTriEx/EpCAM transformed and un-induced bacteria over time indicated 
slower growth for the pTriEx/EpCAM transformed bacteria compared to the same bacteria 
transformed with the control plasmid (see Figure 3.3).  The recombinant plasmid transformed 
Tuner cells reached logarithmic growth phase after 3 h while the control cells were more than 
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half-way through the logarithmic phase at 3 h of growth with an optical density above 1.1.  The 
recombinant plasmid transformed cells took almost 18 h to reach stationary phase.  
 
Figure 3. 3: Growth curves of Tuner (DE3)pLac  bacteria transformed with pTriEx 4 Neo/ 
EpCAM-V5-His6 and a control plasmid. The graphs show the rate of growth of the un-induced 
bacteria from initial media inoculation through the stationary phase. 
 
The slower growth rate is an indication of inhibited growth due to the recombinant plasmid. The 
OD measurements of cells induced with different IPTG concentrations showed a decrease in 
intensity with increasing IPTG concentration after 2.5 h of induction (see Figure 3.4).  At lower 
IPTG concentrations of 2.5 and 10 μM cell growth occurred at almost the same rate as for un-
induced cells cultured for the same time frame. 
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Above 100 μM IPTG the cell growth process was slower and at the maximum inducer 
concentration of 1 mM there was no change in optical density compared to the un-induced 
starting culture.  In contrast however, control cells induced with 1 mM IPTG showed a slightly 
higher OD after 2.5 h of induction than the 0 mM IPTG control cells incubated for the same time 
period.  The results thus indicate that induction of protein expression with IPTG exerted a 
growth-inhibiting effect on the cells leading to under-production of the recombinant protein by 
the bacteria as determined by western blot analysis.  
 
Figure 3. 4: Optical density measurements of un-induced and IPTG induced transformed 
bacteria cells, showing the effect of the recombinant pTriEx/ EpCAM plasmid on the growth of 
the cells (Ep Tuner) at various IPTG concentrations. Control cells (Ctl Tuner) were induced at 0 
and 1000 μM IPTG levels to determine the effect of the inducer on cell growth. 
 
To test the effect of temperature on the ability of the recombinant colonies to produce EpCAM, 
the cells were induced at IPTG concentrations of 500 μM and 1 mM and incubated at 10, 25 and 
32 °C.  SDS-PAGE with gelcode blue staining showed no over-expression of proteins (see 
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Figure 3.5A). Results of OD measurements showed increased cell density with increasing 
temperature (see Figure 3.5B), however no protein over-expression was observed for the bacteria 
cultures.   
 
Figure 3. 5: The effect of temperature on A) protein over-expression in IPTG induce cells 
determined by electrophoresis with Gelcode Blue staining and B) the growth of the bacteria cells 
under different temperature conditions as determined by OD measurements.  
 
Studies have shown that some mammalian membrane proteins exert a toxic effect on the 
bacterial expression hosts in addition to the lack of post translational modification mechanisms 
in bacteria.  Thus, these proteins cannot be produced using bacterial expression systems.32  
Western blot analysis performed on the bacteria cell lysates indicated the absence of rEpCAM in 
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the molecular weight range for this recombinant protein.  Also, no degradation products were 
detected that would indicate possible synthesis and breakdown of the protein by the bacteria. 
3.3.3 Mammalian Expression of rEpCAM 
Mammalian expression of rEpCAM was was next attempted using three different cell 
types. BHK cells were selected for transfection studies due to the robustness of this cell type and 
its widespread use in protein expression studies,7, 33 while Hep 2 cells were chosen for their 
epithelial cell property to test their ability to correctly fold and post-translationally modify and 
generate high yields of the rEpCAM.  Cos 7 cells are used in episomal expression studies due to 
the SV40 large T antigen which allows episomal vectors to induce protein generation without 
genomic integration of the plasmid DNA.34  Figure 3.6 shows the results of mammalian 
expression studies using these cell types.  Western blots of lysates from the three cell types, 
SDS-PAGE separated under non-reducing conditions and without prior heat denaturation of the 
lysates, were performed with anti-EpCAM, anti-histidine and anti-V5 primary antibodies.  The 
anti-histidine antibody was not effective for detecting the recombinant protein and was not used 
in subsequent analyses.  Western blots performed with anti-V5 and anti-EpCAM antibodies 
produced better results.  Anti-EpCAM was more effective at detecting the native form of the 
rEpCAM while the anti-V5 antibody was more appropriate for identification of the denatured 
form of rEpCAM. 
Western blots indicated, as expected, that for equal total protein levels of lysate the Cos7 
cells produced higher EpCAM levels compared to BHK or Hep 2 cells due to episomal 
expression of the protein in Cos 7 cells (see Figure 3.6).  Anti-EpCAM western blots of lysate 
proteins electrophoresed under non-reducing conditions showed a band for EpCAm at the 
expected molecular weight of approximately 40 kD in the Hep 2 lysate and higher molecular 
weight band for the Cos 7 lysates while the BHK lysate showed no EpCAM band (see Figure 
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3.6A). The blots carried out using anti-V5 antibody showed multiple bands of monomeric and 
multimeric forms in the Cos 7 lysates of the recombinant protein while the Hep 2 and BHK 
lysates showed single bands of the monomeric recombinat protein at ~40 kD (see Figure 3.6A).   
 
 
Figure 3. 6: Western blots of rEpCAM expression in three different mammalian cells. In A) 
lysates  from Cos 7, BHK and Hep2 cells obtained 5 days after transfection were mixed in native 
sample buffer and immediately separated by SDS-PAGE on 10% tris-HCl gel prior to 
electrotransfer to nitrocellulose for western blotting using antiEpCAM and anti-V5 primary 
antibodies. In B and C, the lysates form stable transfectants were reduced with dithiothreitol and 
heat denatured prior to SDS-PAGE separation and western blot analysis using anti-V5 antibody. 
Image C also shows loss of rEpCAM expression by BHK and Hep2 cells after sub-culturing for 
between 4 to 5 passages. 
A western blot carried out on dithiothreitol (DTT) reduce lysates showed higher levels of the 
recombinant protein in Cos 7 lysates compared to the Hep 2 and BHK  lysates for the same total 
protein content loaded on the gels (Figure 3.6B).  Over-expression of the protein in Cos 7 cells 
may have lead to formation of the observed multimeric aggregates generated in the western blots.  
However, it was observed in subsequent western blots that multimeric bands observed for Cos 7 
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cell were lost in transfected daughter cell culture lysates due to a progressive decline in the 
protein expression levels through sub-culturing of the cells, until a steady level of monomeric 
rEpCAM remained. 
Prolonged production of the recombinant protein in the transfected cells at a constant 
level of expression is important for the generation of adequate amounts of the protein for 
downstream processes.  Thus, the ability of each cell type to sustain protein production over 
several weeks of culturing was determined by western blot of transfected and stabilized BHK, 
Hep2 and Cos 7 cells.  The transfected cells were cultured under antibiotic selection for two 
weeks to produce stabilized transfectants.  The cells were then split and the cultures expanded 
over several passages for storage and protein production. Results indicated that production of the 
recombinant protein in BHK and Hep2 cells declined and was completely inhibited after the 
fourth passage of cells although the cells continued to grow in the presence of the antibiotic 
(Figure 3.6C).  This may be attributed to the effect of genomic integration of the recombinant 
DNA on protein production leading to strict regulation of recombinant protein production by the 
cells’ transcriptional and translational mechanisms.16  Thus, rEpCAM expression was down 
regulated in daughter cells and with time the sequence may have been completely eliminated 
from the genome of BHK and Hep2 cells.  On the contrary, in transfected Cos 7 cells a steady 
level of protein production was maintained up to about the eleventh passage before dropping off.  
The prolonged expression of rEpCAM in Cos 7 cells compared to the BHK and Hep2 
transfectants is due to the episomal expression in these cells.  However, it appeared that with 
time the plasmid copy numbers may have decreased in daughter cells until rEpCAM production 
was solely regulated by the Cos 7 cells transcriptional and translational mechanisms leading to 
loss of rEpCAM production over time.  It has also been reported that BHK and Cos cells are 
generally more suited for transient expression of proteins.  Because of the extended expression 
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time obtained with Cos7 cells transfected with pcDNA/EpCAM, this cell line was selected for 
production and purification of our recombinant protein.  
3.3.4 Extraction and Affinity Purification of rEpCAM from Mammalian Cells  
In order to maximize protein solubilization in non-denaturing detergent various 
detergents were tested for their ability to effectively solubilize proteins in the cells by comparing 
the total protein contents of supernatant and pellet fractions of lysed recombinant cells.  The 
percentage of total protein obtained for the supernatant fractions solubilized using four mild 
detergents were compared to SDS lysed cells (see Table 3.1).  
Table 3.1: The mammalian cell solubilizing effiency of four mild detergents in comparison to 
SDS in terms of total protein content of lysate produced used in mammalian cell lysis. 
 
 
NP40 had the highest percentage of supernatant total protein content (95.5%) of the four mild 
detergents with DOC having the lowest percentage of 81%.  NP-40 was therefore the detergent 
of choice for cell lysis. 
Utilizing a lysis buffer of Nonidet P40 detergent in Tris buffered saline (TBS-NP) with 
sodium molybdate, transfected Cos 7 cells were easily solubilized and subsequently centrifuged 
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to remove solid material. The supernatants obtained were analyzed by western blot analysis for 
rEpCAM and used in the protein purification studies. Affinity purification of solubilized 
rEpCAM from Cos 7 cells was accomplished using cobalt chelated resin.  The incubation time 
and buffer composition were parameters optimized to selectively remove non-specifically 
adsorbed proteins while retaining the bound rEpCAM.  Initial studies were carried out to 
determine the incubation time required for complete binding of the protein to the resin.  
Following the manufacturer’s protocol  for affinity binding of histidine tagged proteins to the 
Talon resin, clarified lysate was incubated with one fifth its volume of resin and incubated at 
room temperature for 2 h or overnight at 4 °C prior to washing with NP-40 buffer containing 
different imidazole concentrations.  Results obtained indicated that longer incubation times at 
4 °C were required to efficiently bind rEpCAM to the resin.  At shorter incubation times up to 2 
h approximately 93% of the rEpCAM was found in the unbound fraction.  The longer incubation 
time requirement for protein binding may be a result of the hexahistidine tag being less 
accessible requiring a longer contact time for proteins to interact with the affinity resin.  This, 
observation was based on western blot results of lysate and purified protein fractions detected 
using both anti-EpCAM and anti V5 monoclonal antibodies. It was observed in our studies that 
the anti-EpCAM antibody was more effective at detecting native rEpCAM in the lysate 
compared to the affinity purified protein while the anti-V5 antibody was more effective at 
detecting the affinity purified, denatured and reduced forms of the protein.  This indicated that in 
the denatured and slightly unfolded state the V5 epitope tag was more accessible for binding to 
its antibody.  Also as mentioned earlier in the protein expression section of this paper, western 
blots carried out on undenatured lysates using antibodies against EpCAM, V5 and C-terminus 
hexahistidine tag showed no rEpCAM band using the anti-histidine antibody probably due to 
inaccessibility of the histidine tag.  Native EpCAM has been proposed to exist in epithelial cell 
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membranes with adjacent molecules interacting laterally through the EGF2-like domain of the 
protein molecules.35, 36  By expressing the bulk of the protein, the ability of the recombinant 
molecules to associate in this manner may to some extent have caused shielding of the 
hexahistidine tags, necessitating a longer incubation time with the IMAC resin in order to induce 
binding.  Western blot results also showed that low levels of the protein were left in the unbound 
fraction even after overnight incubation of lysate with the resin although the loading capacity of 
the resin was not exceeded in the experiments (see Figure 3.7).  Thus, purification steps were 
optimized to ensure optimum protein binding and maintenance of native structure of the protein. 
Buffer components play an important role during affinity purification of proteins. While some 
additives such as Tris can compete with the histidine tag for binding spots on the resin, other 
components such as detergents, reducing agents can denature the protein. Buffer components 
such as glycerol or ethylene glycol may be added to stabilize protein structure during the 
washing and elution stages of purification.  Thus, in this study we varied buffer composition in 
terms of imidazole levels, addition or exclusion of BME in the wash buffer to provide the 
optimum conditions for removal of non-specifically bound proteins.  Figure 3.7 shows a western 
blot of fractions from IMAC purification of Cos 7 lysate.  Bound protein was treated with 
different levels of imidazole in solubilzation buffer to wash and elute the recombinant protein.  
Results indicated that at the Tris concentration of 50 mM used in the cell lysis buffer, rEpCAM 
was eluted from the rein at imidazole concentrations as lo as 25 mM due to interference of tris 
with the binding interaction between the cobalt and rEpCAM.  Imidazole concentrations between 
1 and 75 mM were tested in wash buffers to remove weakly bound histidine containing proteins.  
From figure 3.7 it was observed that the bulk of bound protein was removed at imidazole 
concentrations below 100mM.   
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Figure 3. 7: Optimization of IMAC purification protocol for batch purification of rEpCAM from 
Cos 7 lysate using 0.09% NP40 in TBS. The Western blot image shows elution of rEpCAM at 
imidazole concentrations as low as 25 mM. 
 
Analysis of SDS-PAGE gels of wash, elution and resin extract fractions by gelcode blue 
staining showed the presence of non-rEpCAM proteins in all the fractions indicating that the use 
of imidazole to selectively remove non-specifically bound proteins was ineffective (see Figure 
3.8).  To test the possibility that the non-specifically bound proteins were present due to strong 
interactions, such as disulphide bond formation, bound protein was treated with a 10 nM BME 
wash buffer for at least 20 min prior to washing with increasing imidazole concentrations.  
Results indicated that although some slight improvement was obtained with the use of BME the 
rEpCAM protein could not be detected with anti-EpCAM antibodies in a western blot due to 
disulfide bond reduction and unfolding of the protein.  Increasing the NP-40 concentration to 
above 0.25% in wash buffers also led to loss of the rEpCAM in the wash buffers (results not 
shown).  In subsequent experiments, reducing the Tris concentration to 25 mM in the wash and 
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elution buffers and diluting the lysate to half its initial concentration to decrease tris levels led to 
increased binding of rEpCAM to the resin during the overnight incubation period.  At the 25 mM 
Tris concentration, imidazole levels up to 25 mM could be used to wash the resin bound 
rEpCAM without significant protein losses.  However, gel staining of the eluted fractions still 
showed the presence of other proteins at significantly higher levels than the rEpCAM protein. 
Pre-concentrated eluate re-incubated with Talon resin in a second affinity purification step aimed 
at removing non-specifically interacting proteins resulted in re-binding of all proteins present in 
the starting fraction to the resin (see Figure 3.8).  This indicated that the non-rEpCAM protein 
present in the eluate fractions contained surface exposed histidine clusters capable of very strong 
interactions with the IMAC resin.  These protein contaminants were unfortunately expressed at 
much high levels compared to the target protein. Although the Talon resin was designed to 
selectively bind oligohistidine-tagged recombinants for one step purification of the desired 
protein, our recombinant proved to be difficult to purify in a one step process due to the 
requirement for well exposed histidine tags for enhanced binding to the IMAC resin.  This 
finding necessitated the use of another technique in further purifying our protein target. 
SDS-PAGE of lysate and purification fractions showed that after extensive washing of 
the bound protein with increasing imidazole concentrations up to 25 mM prior to elution with 
500 mM imidazole, the bands of proteins in the the eluate fractions were well resolved to allow 
excision of the rEpCAM band without impurities.  Thus, electrophoretic separation of the 
affinity purified protein could be carried out with extraction of the protein by electro elution. 
With this approach 100% electrophoretic purity of the target protein can be achieved. By 
combining this technique with affinity purification, the probability of co-eluting non-target 
proteins with the desired protein can be greatly reduced and the purification time decreased 
considerably.   
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Figure 3. 8: A western blot (above) and gel images of fractions from a two-stage IMAC 
purification of rEpCAM from Cos 7 lysate showing the presence of rEpCAM in addition to non-
EpCAM protein contaminants present in the elution fractions. Symbols used for the fractions 
collected are : L-lystae (1), U-unbound (2), w-wash (3, 4, 11, 12), E-eluates (5, 6,; 13, 14), B-
resin (7, 15), S-EpCAM standard, P- positope (8), E2-ultrafiltered eluate (9), EU- unbound eluate 
(10), M-markers. 
 
In our studies, eluates of affinity purified rEpCAM were pre-concentrated and 
electrophoresed on 10 % polyacrylamide gel using a 0.05% SDS Tris / glycine buffer.  The gel 
was stained with E-zinc reversible stain and the bands in the molecular weight range 40 to < 50 
kD were excised, destained and electro eluted.  Two distinct bands were observed in this 
molecular weight range and were identified by western blot as rEpCAM (see Figure 3.9) using 
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both anti-EpCAM and anti-V5 primary antibodies. The two bands may be a result of different 
levels of glycosylation of the protein.   
 
 
Figure 3. 9: Western blots of electro elution fractions of IMAC purified rEpCAM. Western blots 
were carried out with anti-EpCAM and ant-V5 primary antibodies to determine retention of 
native structure of the protein. 
 
Also the anti-EpCAM western blot results confirmed retention of native structure after the 
purification process.  Analysis of the band intensities for the rEpCAM protein on the western 
blot images using ImageQuant version 5.2 (Molecular Dynamics Sunnyvale, CA) indicated at 
least 75% recovery of the affinity purified protein after electro elution. 
3.4 Conclusion 
Thus, by combining a one-step IMAC procedure with electrophoresis and electro elution 
a more selective approach to obtaining a target protein in highly purified form and with the 
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required native conformation was achieved.  With the demand for more rapid techniques for 
generating biomarkers for developing analytical techniques in disease management, the ability to 
integrate several biochemical processes efficiently would enable researches to achieve results in 
a more timely fashion.  Microfluidic devices built on polymeric platforms provide the means to 
achieving this goal. The ability to incorporate several analytical processes such as the aptamer 
selection process, electrophoresis and other chromatographic processes in microfluidic devices 
makes it possible to combine protein target generation and purification with affinity agent 
selection on a scale that allows high throughput and rapid generation of analytical reagents for 
disease diagnostics without the use of large amounts of target.  We have demonstrated the 
production of electrophoretically pure rEpCAM in its native folded state using IMAC and 
electrophoretic techniques.  Further work will involve incorporation of the technique in 
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Chapter 4 Immobilization of Aptamers onto Poly(Methyl 
Methacrylate) Polymer, PMMA, Substrates for Aptamer Sandwich 





The analysis of protein biomarkers in biological samples is of great importance in the 
area of proteomics, diagnostics and drug delivery.  In many cases, a large panel of proteins must 
be analyzed simultaneously in a sample that contains a large number of potential contaminants 
and to complicate matters, these biomarkers must be quantified with the expression level of the 
targets spanning many orders of magnitude.1  For example, tumor markers such as the 
glycosylated mucin protein MUC1 over-expressed and aberrantly glycosylated on the surfaces of 
cancer cells and the prostate specific antigen (PSA) are shed at low levels into the bloodstream of 
adenocarcinoma patients and serves as serum biomarkers in commercial serum tumor marker 
assays.2, 3  
High throughput protein biomarker analysis techniques, such as immunoassays in 
microtitre plate format and protein microarray technologies, in many cases provide the ability to 
simultaneously screen for a large panel of these biomarkers and can produce the ability to deliver 
the quantitative information required, even when the targets are present in a large excess of 
interferences.1, 4, 5  Protein microarrays and biosensors utilize high affinity agents such as 
antibodies, peptides or nucleic acid aptamers, which confer specificity and selectivity in target 
identification without sample clean up procedures.1, 6, 7  Protein microarrays have been adapted to 
the current DNA microarray technology to make use of the commercially-available array 
equipment and confocal scanning systems in producing the arrays and reading their results, 
respectively.4, 8, 9  Three major immunoassay formats exist for protein arrays. These are the direct 
assay or reverse-phase immounoassay in which the protein of interest and the standards are 
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immobilized on a platform and probed with a labeled monoclonal antibody;3, 8 the antigen 
capture assay which utilizes an immobilized antibody for the capture of pre-labeled antigen; and 
the sandwich immunoassay which utilizes two antibodies to capture and detect the unlabeled 
antigen.8  The sandwich assay is the most effective and preferred means for target analyte 
identification in complex matrices due to its high sensitivity and stringency through the use of 
two antibodies .10 
 Despite advances made in refining immunoassays for microarrays and biosensors several 
problems exist which limit the application of antibody microarrays.  These include antibody 
cross-reactivity with cellular proteins, difficulty in the development of sets of antibodies for 
different epitopes on a target, stability of the immobilized antibody and the difficulty in adapting 
current protein assay techniques to microarray format.4, 8  With the advent of nucleic acid 
aptamers some of these limitations may be reduced since, for example, the coupling chemistries 
utilized in DNA microarrays are applicable to aptamers and it has been reported that aptamers 
exhibit less cross reactivity compared to antibodies.1  
Aptamers are short single stranded oligonucleotide affinity elements which bind with 
high specificity and selectivity to their targets. They are generated for analytes of interest 
through systematic evolution of ligands by exponential enrichment (SELEX).11  Aptamer targets 
range in size from as small as 100 daltons to very large targets such as cells.12-14  In addition, 
aptamers are capable of binding target molecules with specificity comparable to monoclonal 
antibodies through an induced-fit binding mechanism.15  Production methods for aptamers via 
solid phase synthesis make them relatively simple to produce compared to antibodies. They are 
chemically stable, less susceptible to irreversible denaturation, easily chemically modified and 
can thus be readily immobilized onto a variety of functional supports without affecting their 
recognition function.16  Their smaller size compared to antibodies provides a better chance of 
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generating aptamers to different epitopes on a protein target and also increasing the surface 
packing density of arrays and biosensors for increased assay sensitivity.16, 17  
The use of aptamers in protein array and biosensor development has been studied by 
various researchers using fluorescence or electrochemical detection methods for target 
identification by direct target labeling or sandwich assay. In these studies glass, silicon or 
polymeric substrates were employed as aptamer immobilization platforms.18-20 For example, in a 
study by Collet et al (2005), functional RNA microarrays were developed on commercially 
available streptavidin coated microarray slides using an automated arrayer for spotting and a 
commercial microarray scanner for the readout. Test analytes were pre-labeled with fluorescent 
dye for their detection.7 In separate studies by the same authors, conditions were optimized for 
the production of aptamer microarrays in an attempt to determine the most suitable buffer and 
pH to use for simultaneous analysis of different protein biomarkers in a given sample.19, 21  In 
their studies aptamers selected under different buffer conditions during SELEX were 
immobilized on glass substrate via streptavidin-biotin interaction and assayed using various 
buffers and at different pHs to create optimum conditions for simultaneously identifying 
different pre-labeled protein biomarkers.  
Sandwich assays using immobilized aptamers and labeled antibodies were developed for 
optical detection of biomarkers.2, 22 Ferreira et al (2008) developed a sandwich enzyme-linked 
immunosorbent assay (ELISA) using a biotinylated aptamer and monoclonal antibody for the 
detection of mucin protein, MUC1.2  In a separate study by Kirby et al., streptavidin-agarose 
bead with immobilized aptamers were used for the detection of protein targets using an 
electronic tongue sensor array.22  The sandwich assay format was demonstrated using anti-ricin 
aptamer as capture element and a fluorophore labeled antibody for detection of the target.  
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Although dual-aptamer sandwich assays have been demonstrated with electrochemical 
detection using enzymatic signal amplification, no reports are available on the direct 
fluorescence detection of target proteins using the sandwich assay method. Electrochemical 
detection of enzymatic signal amplification for biosensors based on aptamer sandwich assays 
was demonstrated in a study by Ikebukuro et al.23  In this study the authors developed an 
electrochemical biosensor for thrombin using a glucose dehydrogenase (GDH) linked aptamer 
sandwich-type assay. A GDH-labeled anti-thrombin aptamer was used in conjunction with a 
thiolated capture aptamer immobilized on gold substrate in detecting the protein. The 
electrochemical signal was generated by the action of the GDH enzyme on its quinone 
substrate.23 
An important contributor to performance of nucleic acid arrays and biosensors in terms of 
reproducibility, probe density and availability is the immobilization of the capture element.24  
Various immobilization chemistries are available for aptamer attachment on different substrates 
in biosensor and microarray development. These include covalent, cross-linking and non-
covalent binding interactions such as affinity binding, adsorption and absorption.4, 20, 25 One of 
the most widely used non covalent immobilization chemistries is the streptavidin-biotin 
interaction due to the high affinity of the biotin molecule for streptavidin.24  Covalent attachment 
is the most common commercial method of nucleic acid immobilization on many supports due to 
its simplicity, higher packing density and the ease of derivatizing nucleic acids during synthesis 
depending on the immobilization surface and covalent linkage employed.24, 26, 27   
To provide flexibility and enhance binding interaction between the capture element and 
the target, long linkers can be incorporated at the end of the capture element to reduce steric 
hindrance after immobilization.17  Our group recently reported on the effect of linker length on 
the binding specificity of a thiol-terminated aptamer immobilized on gold slides to its target, 
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thrombin, in studies using Surface Plasmon Resonance.  Results indicated that by utilizing a 
polyethylene glycol linker, a 4-fold increase in the binding capacity of the self-assembled 
monolayer created was achieved compared to the aptamer monolayer without the polyethylene 
glycol linker.28   Thus, by designing the capture aptamer with a linker to further extend it from 
the surface of the support, enhanced binding interaction with the target can be achieved.  
In an attempt to develop rapid, low cost, disposable single use components in diagnostic 
bioassays, plastic substrates are providing a viable alternative to glass-based supports. Several 
thermoplastic polymers have been used to fabricate bioanalytical devices including polystyrene, 
polycarbonate 29 and poly(methyl methacrylate), PMMA, all employing different immobilization 
chemistries.20  Many polymers have good optical clarity for reading microarrays via optical 
techniques, with evolving chemical modification procedures appropriate for ligand attachment.24 
In addition, these materials are easily molded for generating complex microfluidic architectures 
in the development of integrated microdevices.30  In our laboratory, PMMA and PC have been 
used for a variety of different devices and applications, including those that require 
immobilization of probes, such as oligonucleotides, for DNA microarray applications.31, 32 
  Immobilization of nucleic acid ligands onto PMMA and PC surfaces has been achieved 
through ultraviolet 33 radiation activation of the polymers to generate carboxylic acid groups as 
scaffolds for carbodiimide coupling of anime terminated oligonucleotides to the polymer surface. 
Studies have been carried out to determine the optimum UV exposure time for polymer 
activation in order to generate a high density of functional groups and to determine which 
polymer provided the best signal-to-noise ratio (SNR) for optical readout and surface loading of 
the recognition element.31  These studies found PMMA to be particularly attractive for DNA 
microarray studies compared to  PC due to its superior optical properties and also, it showed 
significantly lower levels of non-specific adsorption of targets.31  In another study by Fixe et al, a 
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one-step immobilization of aminated and thiolated DNA molecules onto unmodified methyl 
esters of PMMA was carried out.20  Results showed immobilized probe densities greater or 
equivalent to those obtained by commercially available immobilization methods.  
The focus of this study was to develop dual-aptamer sandwich assays on PMMA 
substrates using direct fluorescence detection without signal amplification techniques. As a 
model for these investigations, thrombin and PDGF-BB were used, because these proteins serve 
as biomarkers of different diseases and are present in serum.  Thrombin has been widely studied 
for aptamer production and has two DNA aptamers that recognize different epitopes on the 
protein.34  PDGF exists as a dimeric protein with three isoforms, PDGF-AA, PDGF-BB and 
PDGF-AB.  An aptamer developed toward PDGF has high affinity for the B chain of the 
protein.35  Using thrombin and its aptamers we first determined the most suitable aptamer for 
immobilization onto the PMMA substrate with subsequent capture of the target by considering 
the ease of G-quartet structure formation of the PMMA immobilized aptamer and also the effects 
of heat treatment on the adoption of the G-quartet structure.  Dual-aptamer sandwich assays were 
then performed using a fluorophore-labeled aptamer for direct detection of thrombin. Conditions 
were optimized for a one-step covalent attachment of aptamers to UV-modified PMMA by 
carbodiimide coupling chemistry, to ensure optimal aptamer density and uniformity in 
immobilization for more efficient and enhanced target binding to the PMMA chip.  Sandwich 
assays were developed for thrombin and PDGF-BB protein using different aptamers for thrombin 
and the same aptamer for PDGF protein with minimal assay performance steps and shorter assay 
time.  
4.2 Experimental 
4.2.1 Reagents and Materials 
Aptamers used in this study were obtained from Integrated DNA Technologies 
(Coralville,IA) and are shown in Table 4.1.  Nuclease-free water, 1-ethyl-3-(3-
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dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxy succinamide (NHS), 
Tris(hydroxyamino) methane (Tris), 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid 
(HEPES), 2-(N-morpholino)- ethanesulfonic acid (MES), sodium chloride (NaCl), magnesium 
chloride (MgCl2) and potassium chloride (KCl) were obtained from Sigma-Aldrich ( St. Louis, 
MO). PMMA sheets of 0.5 mm thickness were purchased from GoodFellow (Berwyn, PA), N-
methyl mesoporphyrin IX (NMM) was obtained from Frontier scientific (Logan, UT), Thrombin 
was purchased from Haematologic Technologies (Essex Junction, VT) and PDGF-BB and AB 
from R&D Systems (Minneapolis, MN). 
4.2.2 Methylmesoporphyrin IX (NMM) Fluorescence Enhancement Test G-Quartet Structure 
Formation of Immobilized Thrombin Aptamers 
 
PMMA  sheets of 0.5 mm thickness were UV activated for 15 min (wavelength 260-300 
nm) and then treated with 10 μg/ mL each of the thrombin aptamers, HD1 (sequence B1) and 
HD22 (sequence A) given in Table 4.1,  in PBS buffer (pH 7.4) containing 40 mM NHS and 50 
mM EDC  for 4 h at room. The aptamer modified chips were rinsed with nuclease-free water and 
stored at 4 °C overnight.  To determine the conformation adopted by the immobilized thrombin 
aptamers in solution, the NMM fluorescence enhancement test was performed.36  Absorbance 
measurements were carried out on 40 μM NMM in Tris buffered saline (TBS) and phosphate 
buffered saline (PBS) to determine the appropriate excitation wavelength using an Ultrospec 
4000 UV/visible spectrophotometer (Pharmacia Biotech, Cambridge, England).  One centimeter 
wide strips of thrombin aptamer modified PMMA were either dipped in TBS containing 1 mM 
MgCl2 and 5 mM KCl at room temperature, or dipped in the buffer at 80 °C and allowed to cool 
to room temperature. Each PMMA strip was transferred to a 1 μM solution of NMM in a 
fluorescence cuvette and aligned against one wall of the cuvette perpendicular to the 
fluorescence emission collection path. Fluorescence measurements were obtained on a Fluorolog 
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fluorimeter (Yvon Jobin Inc., Edison, NJ) between 550 and 750 nm at an excitation wavelength 
of 400 nm. UV-modified PMMA strips without immobilized aptamers served as control chips. 
Table 4. 1: Sequences of DNA aptamers of thrombin (A-D), PDGF (E and F) used in sandwich 
assay development and the aptamer (G), a DNA variant of the prostate specific antigen aptamer, 
used for optimizing the EDC/NHS immobilization protocol on PMMA. Abbreviations used in 
the table are: AmMC6 = primary amine modification with a six carbon linker, iSp9 and iSp18 
represent the internal spacers triethylene glycol and hexaethylene glycol respectively. The 
internal spacer, iSp18, was used to further extend immobilized aptamers from the surface to 
reduce steric effects and improve interaction of the aptamers with their targets. 
 
 
4.2.3 Aptamer Sandwich Assay for Thrombin by Laser Scanning Confocal Microscopy (LSCM) 
PMMA  sheets of 0.5 mm thickness were activated by UV light (260-300 nm for 15 
minutes) through a 750 mesh Nickel TEM grid (SPI Supplies, west Chester ,PA) to generate a 
grid network of 25 μm2 areas of activated surface separated by 8.6 μm  wide unmodified regions 
that were not exposed to UV light. The UV-modified PMMA sheets were cleaned by sonication 
in MilliQ water for 2 min and air dried. A 1.18 μM concentration (~ 10 μg/ mL) of aptamer A 
(see Table 4.1), was immobilized on the UV modified PMMA sheets by carbodiimide coupling 
chemistry using 40 mM NHS and 50 mM EDC in phosphate buffer (pH 7.4). The reaction was 
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allowed to proceed for 4hr at room temperature and the HD22 immobilized chips were rinsed 
with deionized water and stored at -20 °C until required for further use.  
 Sandwich assays were performed in PBS buffer containing 10 mM KCl, 140 mM NaCl 
and 1 mM each MgCl2 and CaCl2.  A 2.5 μM fixed concentration of aptamer B2 (table 1) was 
incubated for 10 min with various concentrations of thrombin ranging from 0 – 1 μM at room 
temperature. Twenty-five microliter aliquots of each HD1-thrombin sample was evenly 
distributed onto 1” x 0.2” chips of HD22-immobilized PMMA and the assays incubated 
overnight at 4 °C.  The chips were then rinsed with PBS and deionized water and dried.  Ten 
milligrams per milliliter BSA were similarly incubated with 2.5 μM aptamer B2 and an HD22 
chip and prepared for analysis. The assay chips were mounted on microscope slides with cover 
slips prior to LSCM analysis.   
The slides were imaged using a Leica TCS SP2 Spectral Confocal and Multiphoton 
Microscope (Leica Microsystems, Mannheim, Germany) equipped with a photomultiplier tube 
(PMT) detector. Images of the chips were obtained using a 63x oil immersion objective at 633 
nm excitation, a scan rate of 200 Hz and the PMT set at 700 V.  Images were analyzed using 
Image Quant V.5 software (Molecular Dynamics, Sunnyvale, CA). 
4.2.4 Sandwich Assays for Thrombin and PDGF-BB Analyzed Using a Home-Built Near-IR 
Array Scanner  
 
To generate dual aptamer sandwich assays for simultaneous detection of different 
concentrations of thrombin or PDGF-BB on a single chip, approximately 1 μM  of aptamer C 
(for theombin capture) and E (for PDGF-BB capture  (see Table 4.1) were each immobilized 
onto UV-activated PMMA using 40 mM NHS and 50 mM EDC in MES (pH 6.7) buffer 
overnight. The lower pH was selected to ensure protonation of the carboxylic acid groups on the 
PMMA surface for enhanced formation of succinimidyl esters during the coupling reaction.  
Also, a polyethylene glycol linker was introduced at the 5’ end of the aptamers to increase 
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flexibility and reduce steric effects due to immobilization. The aptamer-modified chip was 
dipped in TBS-TPG buffer at 40 °C and cooled to room temperature. The chip was treated with 1 
μL volumes of different concentrations of protein pre-incubated with 3 μM detection aptamer 
(see Table 4.1) in TBS-TPG for 5 min at 37 °C.  The assays were incubated overnight at 4 °C, 
gently rinsed in buffer to remove unbound protein, dried and fixed on a microscope slide with a 
cover slip and scanned at 680 nm excitation on a home-built near–infrared (near-IR) 
fluorescence scanner that has been previously described.31  Briefly, the scanner consisted of a 
670 nm 10 mW laser diode (Thorlabs, Newton ,NJ) for sample excitation, a set of optical filters 
consisting of a neutral density filter (ND 0.6; Thorlabs) and a line filter (670DF20; Omega 
Optical, Brattleboro, VT), a beam splitter (690 DRLP; Omega Optical, Brattleboro, VT), a 40x 
high numerical aperture (NA 0.85)  microscope objective (Nikon, Natick, MA) for focusing the 
laser beam on the array. The fluorescence was collected through the same objective and 
transmitted through a dichroic, 700 ALP longpass and 720 DF20 bandpass filters (Omega 
Optical) and a pinhole to a single-photon avalanche detector (SPAD). Samples were mounted on 
an X/Y translational stage and scanned at a 50.8 μm step-size with a 0.1 s/ pixel integration time.  
Data acquisition was performed using software written in Visual Basic. 
4.2.5 Optimization of Conditions for EDC/NHS Immobilization of Aptamers onto PMMA 
To Optimize the EDC/NHS coupling protocol by shortening the immobilization time and 
increasing the immobilized aptamer density for aptamer immobilization onto PMMA surfaces 
for microarray development, aptamer G in Table 4.1 was used.  Approximately 1μL volumes of 
various concentrations of G (5, 10, 15, 20 and 40 μM) in 50 mM MES buffer (pH 6.7) with 2% 
glycerol, 50 mM EDC and 40 mM NHS were deposited on UV-modified 0.5 mm thick PMMA 
chips. One chip was incubated at 37 °C for 30 min and the other for 5 h, rinsed with deionized 
water and dried.  The aptamer was similarly spotted in 50 mM HEPES buffer (pH 7.2) 
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containing 0.1% PEG 400, 2 % glycerol, 200 mM EDC and 40 mM NHS on UV activated 
PMMA.  Incubation of the chips at 37 °C was for 30 and 80 min in a water bath prior to rinsing 
and drying. The chips were scanned at 680 nm excitation on the home-built near-IR fluorescence 
scanner at a 50 μm step-size and an integration time of 0.1s per pixel.    
4.2.6 Sandwich Assays for Thrombin and PDGF Using Optimized Immobilization Conditions 
UV-modified PMMA chips were treated with 10 μM each of amine terminated HD22 and 
PDGF aptamer (aptamers C and E in Table 4.1) in HEPES buffer with 200 mM EDC and 40 mM 
NHS, by inundating PMMA chips with a capture aptamer in HEPES buffer with EDC/NHS.  The 
aptamer immobilized chips were treated as previously described for sandwich assays with minor 
changes. Instead of an overnight incubation of the sandwich assays, the assays were incubated 
for 1 h at 37 °C and processed for scanning on the near-IR scanner. Concentrations of Cy5.5-
HD1 and Cy5.5-PDGF aptamers were fixed at 1 μM and 500 nM respectively for detection of 
thrombin and PDGF.   
4.3 Results and Discussion 
4.3.1 NMM Fluorescence Test for Evaluating G-Quartet Structure Formation of Immobilized 
Thrombin Aptamers 
 
Schematics of the UV modification and aptamer immobilization onto PMMA and the 
NMM fluorescence enhancement processes are depicted in Figure 4.1A and 4.1B.  The 
immobilized capture element in an array or biosensor plays an important role in the sensitivity of 
the bioassay in terms of its ability to bind the target and its packing density.16, 17  In developing a 
dual aptamer sandwich-type assay for thrombin using two aptamers that recognize different 
epitopes on the protein, an important consideration was the ability of the immobilized aptamer to 
maintain the necessary conformation required for binding the target protein with high affinity. 
The formation of an intramolecular G-quartet structure is essential to binding of thrombin by its 
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aptamers.37 Thus the ability of the immobilized thrombin aptamers to form and maintain the G-
quartet structure may enhance the performance of the sandwich assay.  In order to select the 
more appropriate of the two aptamers for capturing thrombin in a sandwich-type assay, we 
considered the stability of G-quartet structure formation in addition to a higher binding affinity. 
  In a capillary electrochromatographic study by Joyce and McGown (2004), the adoption 
of the G-quartet structure by thrombin aptamers immobilized in a glass capillary was studied 
using NMM dye fluorescence enhancement.36  This dye has been shown to selectively bind the 
three dimensional G-quartet structure of single-stranded DNA leading to fluorescence 
enhancement of the bound dye .38  Results of the NMM fluorescence emission measurements at 
610 nm performed on PMMA immobilized HD1 and HD22 aptamer chips are shown in Figure 
4.1C.  The absorbance maximum of NMM in Tris buffer was determined and an excitation 
wavelength of 400 nm was selected for these fluorescence measurements.  Samples of PMMA 
immobilized aptamer dipped in 1 μM NMM after heating to 80 °C and cooling in Tris buffered 
saline (TBS) showed an increase in fluorescence intensity compared to samples place directly in 
NMM solution without prior heat treatment. This is due to structural re-orientation of the heat 
treated aptamers to form the intra-molecular G-quartet conformation. The HD22 aptamer showed 
the highest fluorescence enhancement after heat treatment due to its higher structural stability 
produced by the formation of a four nucleotide DNA duplex through its 5’ and 3’ ends.37  Even 
in the unheated samples the fluorescence intensity for the HD22 chip was slightly higher than 
that for the HD1 chip.  The HD1c sample showed the lowest fluorescence intensity of all four 
samples. 
Because fluorescence enhancement of NMM occurs in the presence of the G-quartet 
structure, the lower fluorescence intensities obtained for the chips not subjected to heat treatment 
indicated potential DNA conformations other than the quadruplex.  Thus, aptamers immobilized 
 91
on surfaces that require a G-quartet conformation for high target recognition capabilitiy may 
require heat treatment prior to performing the affinity assays to enable formation of the 
quadruplex structure for specific and stable target binding.  Because HD22 showed the highest 
fluorescence enhancement and due to its higher binding affinity for thrombin, we selected HD22 
as the capture element for the sandwich assay and used HD1 as the detection probe. 
 
 
Figure 4. 1: A) Schematic of the UV-modification and EDC/NHS coupling process used in 
immobilizing aptamers onto PMMA, (B) Depiction of the NMM fluorescence enhancement 
assay showing intercalation of the dye to the G-quartet structure of the aptamer resulting in 
fluorescence enhancement. (C) The results of the fluorescence enhancement assays for HD1 and 
HD22 immobilized covalently onto PMMA chips. The aptamer chips were either heat treated at 
80 °C in buffer and cooled prior to immersion in NMM solution (h) or placed in the solution 
without heat treatment (c) with un-functionalized PMMA as the control. Fluorescence emission 
was obtained at 610nm with excitation at 400 nm.  (D) Schematic depicting the aptamer 
sandwich assay performed for thrombin and PDGF proteins on a PMMA substrate with 
immobilized aptamers. 
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4.3.2 HD1-HD22 Sandwich Assay for Thrombin Detection 
One of the potential advantages of using aptamers in detection of protein targets in arrays 
is the ability to spot multiple aptamers capable of recognizing different proteins for doing spatial 
multiplexing and then, reading successful molecular association events by a second aptamer that 
binds to another epitope on the same target, which eliminates the need for labeling the target 
with a fluorophore or other reporting entity.   Because thrombin and its aptamers HD1 and HD22, 
which bind to different epitopes, have been well studied, we used this system as a model for 
investigating the formation of aptamer recognition arrays onto PMMA solid support.   Figure 
4.1D shows a general schematic of the sandwich assay adopted for the protein targets studied 
herein.  Because UV-irradiation of PMMA creates a functional scaffold of carboxylic acids that 
can be subsequently treated with EDC/NHS to covalently attach primary amines through amide 
bond formation,30 initial studies were performed with the PMMA substrate UV-modified through 
a TEM grid to create regions of HD22 aptamer functionalized PMMA and areas essentially 
unmodified by UV radiation and thus, contained no immobilized aptamer.  The HD22 
functionalized chips were treated with target protein and a fixed concentration of 2.5 μM Cy5-
HD1 and imaged by LSCM after an overnight incubation at 4 °C (see Figures 4.2 and 4.3).   
Figure 4.2A shows an image of a 10 nM thrombin sandwich assay chip acquired by 
LSCM showing areas of high fluorescence containing the sandwich assay and regions of low 
signal intensity indicating areas free of any discernible thrombin, which would indicate that only 
the UV-modified regions were able to support the covalent attachment of the recognition 
aptamer. In Figure 4.2B is shown the intensity plot taken from the image shown in Figure 4.2A 
in relative fluorescence units (rfu). As can be seen, the fluorescence intensity dropped to nearly 0 
in those areas not exposed to the UV-radiation through the TEM grid shadow mask, indicating 
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the lack of any thrombin or reporter aptamer non-specifically adsorbing to the PMMA surface, 
consistent with our previous results using PMMA as supports for DNA microarrays.31  
 
 
Figure 4. 2: LSCM analysis of thrombin aptamer sandwich assay on PMMA UV modified 
through a TEM grid showing A) an image of HD22 functionalized chip treated with 10 nM 
thrombin assayed with 2.5 μM Cy5-HD1 with the detector set at PMT voltage of 700 V and B) a 
graphical representation of the chip obtained using ImageQuant analysis. The line drawn across 
the image in (A) represents the sampling section obtained for the profile shown in (B).  Chips 
were incubated overnight at 4 °C prior to scanning. 
Results of LSCM imaging of the aptamer chips showed specificity of the assay for 
thrombin compared to BSA (see Figure 4.3).  A comparison of the average rfu values obtained 
for aptamer-functionalized areas and non-functionalized areas of each sandwich assay chip 
indicated a difference in intensities of the two regions for the thrombin treated chips.  However, 
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no difference in intensity values was obtained for the HD22-chip treated with 10 mg/mL BSA 
and the HD1-Cy5 detection aptamer.  
 
Figure 4. 3: ImageQuant analysis of LSCM images acquired for thrombin aptamer assays 
performed on PMMA that was UV-modified through a TEM grid. The bar graph shows intensity 
differences of the LSCM images of HD22 functionalized and unmodified regions of the PMMA 
chips generated for different thrombin concentrations, BSA and the control samples.  The blank 
is an HD22 immobilized chip treated with Cy5-HD1.  A chip treated with 10 mg/ mL BSA was 
used in testing specificity of the assay for thrombin.  Images were obtained at a fixed PMT 
voltage of 700 V. 
 
Also, the average intensity for the BSA chip was lower than values obtained for thrombin treated 
chips indicating specificity of the assay for thrombin.  From Figure 4.3 the highest values were 
obtained for 1 μM thrombin.  Very little change in intensity of the assay was observed for 
thrombin concentrations of 100 nM and below.  This may be due to the limiting effect of the 
surface coverage of immobilized aptamer on the PMMA surface.  Two dimensional plots of the 
images, as shown in Figure 4.2, show non-uniformity in intensity of the assay regions. This is an 
indication of an increased PMMA surface roughness39, 40 which, may affect aptamer 
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immobilization. Also, the use of several pieces of PMMA in generating assays for different 
target concentrations introduced variability in results obtained due to differences in assay 
characteristics between the PMMA chips in terms of PMMA surface topography and the amount 
of aptamer immobilized on each chip.   
Previous reports in our group on the amount of carboxylic acid groups generated on UV-
modified PMMA show that between 0.8 to 1.3 nmoles/ cm2 ( 8 to 13 picomoles/ mm2) of the 
functional group are generated for  10 to 30 min UV exposure times.40  Thus, less than optimal 
immobilization conditions could affect the amount of aptamer immobilized, thereby affecting the 
performance of the assay in terms of the amount of protein bound and the time required for 
binding interactions between the target and immobilized aptamer to occur.  In this experiment 
the carbodiimide coupling reaction was performed in phosphate buffer which has been reported 
to interfere with the EDC coupling of primary amines with carboxylic acid groups.41  
Immobilizations were thus, carried out in MES buffer at pH 6.7 to prevent hydrolysis of EDC by 
phosphate buffer components.41  
In order to generate sandwich assays for the detection of various concentrations of 
protein on a single chip, spots of thrombin and PDGF-BB sandwich assays were respectively 
generated on HD22 and PDGF aptamer-modified PMMA substrates and analyzed using a 
fluorescence scanner built in-house (see Figures 4.4A and 4.4B).  Figure 4.4A shows spots of 
50 % serial dilutions of each protein incubated with 3 μM Cy5.5-labeled detection aptamer on 
aptamer-modified PMMA.  Thrombin concentrations ranged from 0 to 4 μM while PDGF-BB 
concentrations were varied from 0 to 1.85 μM.  Results for the thrombin sandwich assays (see 
Figure 4.4B) showed an increase in intensity of the spots with increasing thrombin concentration, 
an indication of the effectiveness of the sandwich assay in detecting thrombin. The assays for 
PDGF-BB were less effective compared to the thrombin assay. The plot of fluorescence intensity 
 96
versus protein concentration for the PDGF-BB assays showed an increase in signal intensity at 
the higher concentrations of 925 nM and above.  Also, the assays required an overnight 
incubation for detection of the target, an indication that the immobilization conditions were still 
not optimal for performing the assays.  
4.3.3 Optimization of the Aptamer Immobilization Protocol 
We were interested in improving the rate of target binding and assay sensitivity by 
increasing the aptamer surface density through optimization of the immobilization conditions in 
terms of pH and EDC reagent concentration. Variations in the carbodiimide coupling chemistry 
for immobilizing DNA to UV modified PMMA surfaces exist.31, 39, 42, 43 For example, multiple-
step immobilization processes has been reported in which the oxidized PMMA is first treated 
with EDC/NHS in MES buffer at pH 5 to enhance modification of the carboxylic acid groups. 
The amine functionalized DNA to be immobilized is then added in the same buffer to generate 
microarray spots.31, 42  The probe concentrations used for the immobilization processes in these 
studies ranged from 100 nM to 20 μM with incubation times from 1 h to greater than 5 h.  
Reports in literature indicate that although the addition of a succinimide to EDC 
stabilizes the reaction with carboxylic acid groups through the formation of a more stable 
succinimidyl ester intermediate, the reaction of succinimidyl esters with primary amines occurs 
more efficiently at basic pH values at which the primary amines are unprotonated.44  Thus, 
immobilization of the amine terminated capture aptamer may still not be efficient at the acidic 
pH values necessary for EDC modification of carboxylic acid groups and longer incubation 
times may be required at the lower pH to ensure higher coupling efficiency.  This may lead to 
excessive drying of the reaction mixture resulting in non-uniform immobilization of the aptamers.  
Non-uniformity in immobilized oligonucleotide densities have been reported as a condition that 
affects sensitivity of microarrays due to variation in the functional group densities on the 
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surfaces of the immobilization substrate.17 In addition, evaporation of the immobilization 
mixture after spotting leads to higher probe concentration at the outer edge of the spot compared 
to the center leading to non-uniform probe deposition on the support, which affects the 
performance of the assay.17   
 
Figure 4. 4: Near-IR fluorescence images of 1:1 serial dilutions of thrombin (0, 0.125, 0.25, 0.5, 
1.0, 2.0 and 4 μM) and PDGF-BB (0, 0.058, 0.115, 0.231, 0.462, 0.925 and 1.85) were mixed 
with 3 μM Cy5.5-labeled aptamer (aptamer D and F in table 1) and spotted on an HD22 and 
PDGF-functionalized PMMA slides respectively. The slides were incubated overnight at 4 °C 
prior to scanning. The scan rate was 500 μm/s over a scan area of 18 x 20 mm. In (A) thrombin 
samples are represented as T1-T7 and PDGF-BB samples are represented as P1 – P6 in 
increasing order of protein concentration. 
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Thus, to optimize the coupling efficiency for higher aptamer density and uniformity and to 
shorten the time for immobilization of aptamers to PMMA surface, an aptamer amine-terminated 
at the 5’ end and Cy5.5 dye labeled at the 3’ end was used. 
We first carried out immobilization studies on different dye labeled aptamer 
concentrations in MES buffer at pH 6.7 as previously performed for the sandwich assays to 
determine the probe density in terms of fluorescence intensity at shorter incubation times.  In 
another set of experiments using HEPES buffer, we increased the EDC concentration to 200 mM 
to compensate for its rapid hydrolysis in the presence of amine nucleophiles41 and increased the 
pH to 7.2 to create a less acidic environment for better reaction of the succinimidyl ester 
intermediates with the primary amine moieties on the 5’-end of the aptamer.  The amine-
terminated oligonucleotide was added to the buffer containing EDC and NHS and spotted on UV 
activated PMMA.  The incubation temperature was increased from room temperature to 37 °C 
and the incubation time shortened to between 30 min to 5 h for the reaction in MES buffer and 
30 min and 80 min for the HEPES buffer reaction. A 2% glycerol concentration was used in the 
buffers to reduce dehydration of the reaction mixtures during the immobilization process.  
Results indicated that in both buffer systems the average fluorescence intensity of the 
spots obtained across the width of each spot increased with increasing aptamer concentration 
especially at the higher concentrations of 20 and 40 μM (see Figure 4.5A and B). Variations in 
the uniformity of the spot intensities were higher at the shorter incubation time of 30 min (Figure 
4.5A).  By increasing the EDC concentration and increasing the pH to 7.2, the aptamer spot 
intensities increased above the values obtained in MES at the lower pH and lower EDC 
concentration, due to increased reaction rate at the higher EDC concentration and stability of the 
carbodiimide coupling reaction at neutral pH compared to the lower pH.45  The 80 minutes 
incubation in HEPES buffer provided the highest coverage density of the oligonucleotide (see 
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Figure 4.5B).  Based on the results obtained immobilization of aptamers for sandwich assay 
development was performed in HEPES buffer at pH 7.2 for 80 min. 
 
Figure 4.5: A) Images of a one-step EDC/NHS coupling reaction for various concentrations of 
immobilized Cy5.5 labeled aptamer (G) onto UV-modified PMMA with different incubations 
times of I) 30 min and II) 5 h in pH 6.7 MES buffer and III) 30 min and IV) 80 min in pH 7.2 
HEPES buffer, and B) plots of fluorescence intensity of the spots showing the effect of pH and 
EDC concentration on the coverage density of the labeled aptamer.  The MES buffer contained 
EDC at 50 mM while in the HEPES buffer EDC concentration was increased to 200 mM with a 
fixed 40 mM NHS concentration in both buffers.  Imaging conditions are the same as those given 
in Figure 4.4. 
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4.3.4 Sandwich Assay Development Using Optimized EDC/NHS Immobilization Conditions 
In order to further reduce the sandwich assay time, we investigated the effects of 
incubation time on the fluorescence response.  Capture aptamers were immobilized at 10 μM 
concentrations in pH 7.2 HEPES buffer containing 200 mM EDC and 40 mM NHS for 80 min at 
37 °C.  Results of the sandwich assays performed using 1 μM aptamer D for thrombin and 0.5 
μM aptamer F for PDGF-BB detection are displayed in Figure 4.6.  
Plots of sandwich assay fluorescence intensity versus protein concentration showed a general 
increase in intensity with increasing protein concentration.  The slope of the curve for the PDGF 
assay (4.81 cnts/ nM) was sharper compared to that of the thrombin assay (1.42 cnts/ nM) within 
the linear region of each plot (see Figure 4.6 A and B).  This implied higher sensitivity of the 
PDGF assay (see Figure 4.6A) as a result of the lower KD value of the PDGF aptamer.  The 
reported KD value for the PDGF aptamer is 10-10, whereas that for HD1 is between 10-8 and 4 x 
10-7, and 5 x 10-10 for HD22.35, 37 Above a PDGF-BB concentration of 250 nM corresponding to 
an aptamer to protein ratio of 2:1 and below a PDGF concentration of 62.5 nM (4:1 aptamer to 
protein ratio), the fluorescence signal was no longer linear.  This may be attributed to more 
aptamer binding sites being available on the homodimeric protein than there are detection 
aptamers at greater than 250 nM PDGF-BB concentration leading to lower fluorescence intensity 
at the 500 nM concentration.  At 62.5 nM concentration of PDGF-BB and below the amount of 
available protein may have been so low as to cause competition between the capture and 
detection aptamers for the PDGF-BB target, since the same aptamer is used in the capture and 
detection of the protein.  Thus, this limited the linear range of detection to less than an order of 
magnitude.  This problem may be rectified in the development of dual aptamer sandwich assays 
for homodimeric protein targets using the same aptamer in capture and detection, through 
modification of the capture aptamer.  For example, modified nucleotide bases can be 
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incorporated in the capture aptamer sequence to enable covalent attachment of the protein to the 
capture aptamer once bound to the chip surface.46 
 
Figure 4.6: Sandwich assay intensity profiles of A) various PDGF-BB concentrations ranging 
from 0 - 500  nM combined with 500 nM Cy5.5-PDGF aptamer and B) thrombin at 
concentrations between 31 nM and 2000 nM  with a fixed concentration of 1000 nM for the 
Cy5.5-HD1 reporting aptamer. The assays were incubated at 37 °C for approximately 1 h before 
scanning using the near-IR imager.  
 
The use of different aptamers in the capture and detection of thrombin circumvented the 
problem of competition between the capture and detection elements for the target. For the 1 h 
assays performed for thrombin a linear response over one order of magnitude was achieved and 
HD1-Cy5.5 could be used at an excess of 1 μM or more without affecting the assay performance 
(see Figure 4.6B). Thrombin could be detected down to 31.25 nM concentration in a 1 μL sample 
volume. Also it was observed that by using the optimized immobilization conditions for HD22 
aptamer, the assay performance time was drastically decreased to an hour due to enhance binding 
of thrombin to HD22 compared to the overnight incubations required in previous experiments in 
order to detect the protein.  
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4.4 Conclusion 
Aptamers hold promise for the development of bioassays due to their selectivity and high 
specificity. We optimized a one-step EDC/NHS coupling procedure for aptamer immobilization 
onto UV-modified PMMA by using a higher pH of 7.2 and increasing the EDC concentration to 
200 mM to provide increased surface density and uniform coverage of immobilized aptamers for 
enhanced target binding in dual-aptamer sandwich assay development.  We demonstrated the use 
of thrombin aptamers in a sandwich assay with fluorescence detection without signal 
amplification techniques. The thrombin sandwich assay was specific for thrombin and showed 
very little interaction with BSA. Assays were performed for thrombin and PDGF-BB detection 
using the optimized immobilization protocol with a resultant decrease in the assay time and with 
fewer steps compared to the standard immunoassay protocols. Although an emerging class of 
affinity agents, more research on improving the binding affinities of some aptamers will 
eventually allow widespread use of aptamers in a variety of bioassays requiring immobilization 
of aptamers. Future work will involve incorporation of aptamers in PMMA devices for capture 
and detection of biomarkers or for capturing cells in disease diagnosis.   
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Chapter 5 Utilization of an Aptamer Pair in Single Molecule FRET 
Determination of Low Levels of Thrombin 
 
5.1 Introduction 
Some diseases are characterized by the generation of low levels of biomarkers used in 
monitoring their progression and treatment effects.  Hemophilia A and B, genetic disorders, 
which occur due to single point mutations result in prolonged bleeding of affected individuals.1  
Patients with the most common forms of this condition (hemophilia A and B) produce low levels 
of coagulation factors VIII  (FVIII) and IX 2 respectively.3 The mean levels of FVIII and FIX 
determined for normal individuals in plasma are 0.7 nmol/L and 90 nmol/L respectively.1, 4   
Individuals with the disorder produce lower levels of these factors which negatively affect 
hemostasis. Various methods have been developed to detect and monitor the effects and 
treatment of hemophilia. Analytical methods include, clotting time assays, enzyme linked 
immunosorbent assays (ELISA) for the coagulation factors and thrombin generation tests.5-7  
Thrombin, the last coagulation protease in the blood clotting cascade, exists in blood in 
its zymogen form, prothrombin.  When an imbalance in hemostasis occurs due, for example, to 
injury thrombin generation is triggered via a cascade process requiring a host of coagulation 
factors which include FVIII and FIX leading to clot formation.8 The time taken for thrombin 
generation to the level required for clot formation (usually 10 nM thrombin in the initiation 
phase) and the maximum level of thrombin produced during establishment of hemostatic control 
(between 200-800 nM thrombin in the propagation phase) are very important parameters used in 
identifying problems in hemostasis and for monitoring treatment regimes.9  In hemophilia, 
thrombin generation is very slow and thus, clotting based assays can only give qualitative 
information about the condition.  Thus, more universal techniques for monitoring hemophilia and 
treatment therapies have been developed. The thrombin generation assay, first introduced in 
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1953 by MacFarlane and Biggs, is now widely used in monitoring hemophilia therapy.5, 10  This 
technique measures the thrombin generation capacity of plasma by monitoring the enzymatic 
activity of thrombin using chromogenic or fluorogenic peptide substrates.  This allows real-time 
monitoring of the thrombin generation process for detailed kinetic analysis of hemostasis.11  The 
thrombin generation test allows thrombin generation in the nanomolar range to be measured 
using fluorogenic substrate.12 
 Because of the slower process of thrombin generation in hemophilia3 a method sensitive 
enough to allow direct measurement of thrombin at sub-nanomolar concentrations would allow 
studies to be carried out, which could provide more insight into the effects of hemophilia 
treatment options and individual variations in response to treatment regimes.  Analytical 
techniques based on single molecule detection could provide solutions to problems not addressed 
by the current methods for monitoring hemophilia in patients. 
Fluorescence resonance energy transfer at the single molecule  level (smFRET) is a 
powerful spectroscopic technique for studying interactions of biomolecules at the molecular 
level with advantages of being able to reveal the population distribution more directly in 
heterogeneous systems and also provides the opportunity to determine the kinetics of 
unsynchronized complex biochemical processes.13  smFRET can be used to detect rare 
conformational transitions and for detection of transient reaction intermediates which are 
difficult to detect by ensemble FRET methods.  In a real-time smFRET study by Sugawa et al., 
conformational changes in the structure of immobilized Cy3-labeled H-Ras (1-171) protein 
arising from binding of the protein to its substrate labeled with Cy5 dye were determined by 
measuring smFRET intensity in the presence or absence of an effector capable of inducing 
protein denaturation.14 Quantum-dot (QD) FRET-based nanosensors were also used in a 
conformational dynamics study under capillary flow conditions to determine deformation of long 
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DNA strands.15  The smFRET signal was monitored with results indicating greater FRET 
efficiency observed for deformed DNA molecules under flow conditions .15 Thus, smFRET 
technique provides information on the state of individual molecules which would not be 
available under bulk FRET conditions. 
Aptamers have emerged as a class of affinity agents capable of rivaling antibodies in 
bioassay development. These molecules recognize distinct epitopes on their targets and in some 
cases have affinities comparable to monoclonal antibodies.16  Their small size and ease of 
generation and production make it possible to generate aptamers that recognized different 
epitopes on the same target.17  Thrombin has been widely studied for aptamer selection and has 
two aptamers, HD1 and HD22,18 which bind to its exosites I and II respectively making it 
possible to develop assays for thrombin detection either using a single aptamer or both aptamers. 
Highly sensitive aptamer-based methods for protein detection at sub-nanomolar levels have been 
developed which, depend on DNA amplification for protein detection. These include the 
proximity ligation assays which consist of affinity agents linked to DNA primers and a connector 
DNA sequence. The DNA sequences are enzymatically ligated when in close proximity through 
binding of the affinity agents to the target. The DNA is then amplified by polymerase chain 
reaction for detection of the protein.19 This method was used in the detection of platelet derived 
growth factor and thrombin in complex biological fluids.  An affinity-based detection system 
capable of detecting low levels of target without signal amplification in heterogeneous mixtures 
would be an invaluable diagnostic tool for disease detection.  
Heyduk and Heyduk developed a FRET-based aptamer sensor for detection of thrombin 
in heterogeneous mixtures without sample manipulation. 20, 21 The aptamers HD1 and HD22 
were each linked at the 3’ and 5’end respectively to one each of a complementary seven-base 
long oligonucleotide sequence via five hexaethylene glycol internal spacers. The complementary 
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oligonucleotide strands each had a donor or acceptor dye at the end of the short sequence 
opposite to the aptamer attachment end. Co-association of the aptamer beacons with thrombin 
led to enhanced annealing of the short oligo strands leading to increased FRET response.  Thus, 
the sensor allowed selective detection of thrombin in heterogeneous assays.20  
In this study we sought to develop a smFRET-based assay for detection of low levels of 
thrombin in real-time using the aptamer sensors designed by Heyduk and Heyduk. Parameters 
considered included designing the complementary strand to ensure maximum FRET response 
through direct attachment of the dyes to the short complementary oligomers or attachment via a 
short internal linker; The ensemble FRET response of the aptamer sensor in the presence of 
different concentrations of thrombin or prothrombin was also determined to ensure its selectivity 
for thrombin; smFRET determinations were performed in the sub-nanomolar concentration range 
to determine the ability of the sensor to detect single molecule events.   
5.2 Experimental 
5.2.1 Reagents and Materials 
Thrombin and prothrombin used in the determinations were obtained from Haematologic 
Technologies, Inc. (Essex Junction,VM). Short single stranded Cy3 or Cy5 labeled 
complementary oligonucleotide sequences were synthesized by Integrated DNA Technologies 
(Corallville, IA) with or without an ethylene glycol internal spacer between the dye and the 
oligonucleotide strand (sequences: CGC ATC T-/Cy3/-3  and 5’/Cy5/AGA TGC G).  The 
aptamer beacons designed as described by Heyduk and Heyduk  (sequences: 5’/Cy5//C7/AgA 
TgC g-(/hexaethylene glycol/)5-AgT CCg Tgg TAg ggC Agg TTg ggg TgA CT-3’ ; 5’ ggT Tgg 
TgT ggT Tgg-(/hexaethylene glycol/)5-CgC ATC T/C6/-/Cy3/-3’) were synthesized by Midland 
Certified Reagent Company, Inc. (Midland, TX). Reagents for buffer preparation including 
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HPLC grade water, Tris, chlorides of sodium (NaCl), potassium (KCl) and magnesium (MgCl B2 B) 
were obtained from Sigma-Aldrich (St. Louis, MO). 
5.2.2 Ensemble FRET Experiments 
All bulk fluorescence measurements were carried out on a Fluorolog JY Jobin Yvon 
Horiba Spectrofluorometer (Jobin Yvon Inc., Edison, NJ) and absorbance measurements of dye 
labeled oligonucleotides and aptamer sensors were carried out on an Ultrospec 4000 UV/Visible 
Spectrophotometer (Pharmacia biotech, Cambridge, England) to determine the excitation 
wavelengths for the Cy3 and Cy5 labeled oligonucleotides. 
Three prime and 5’ Cy3 and Cy5 end-labeled complementary single stranded 
oligonucleotide sequences synthesized with or without an ethylene glycol internal spacer 
between the dye and each sequence were diluted in nuclease-free water from which 1 μM stock 
solutions in Tris saline buffer (TBS) containing 1 mM MgCl B2 B and 5 mM KCl at pH 7.7 were 
prepared.  Each oligonucleotide sequence was then combined with its complementary strand in 
four different combinations depending on the presence or absence of the ethylene glycol internal 
spacer to a final concentration of 250 nM each. The oligonucleotide mixtures were incubated at 
37 °C for 1 h and cooled to 4 °C in a thermocycler.  Fluorescence determinations on the annealed 
strands were carried out at 532 nm excitation wavelength to determine the best internal spacer 
combination for maximum FRET response. 
For ensemble FRET measurements carried out using the aptamer sensor, samples of 
thrombin and prothrombin at different concentrations ranging from 0 to 250 nM were gently 
agitated at room temperature with 250 nM each of aptamer 5’-HD1-3’-Oligo7-Cy3 and Cy5- 
oligo7-5’-HD22 in TBS (pH 8.5) containing 0.65mg/ mL polyethylene glycol, 1 mM MgClB2B and 
5 mM KCl for 1 h protected from light.  The solutions were excited at 532 nm wavelength and 
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emission collected from 540 nm to 720 nm. The fluorescence intensity measurements obtained 
near the emission maximum for Cy5 were analyzed to determine the changes in FRET intensity. 
5.2.3 smFRET Analysis of Thrombin/Aptamer Complexes 
For smFRET studies 1 nM samples of each aptamer beacon, a combination of the two 
aptamer beacons and the beacons combined in 5 fold molar excess with thrombin were prepared 
in TBS buffer (pH 8.5) with buffer components as above for ensemble FRET measurements. The 
samples were incubated at room temperature with gentle shaking for 30 min and diluted to 30 
pM aptamer concentration prior to analysis on a home –built single molecule detection system. 
5.2.4 Instrumentation for smFRET Determinations 
smFRET measurements were performed using a home-built epi-illumination fluorescence 
system with two detectors as depicted in Figure 5.1.  The excitation source consisted of a 10 mW, 
532 nm laser diode (model: GTEC-500-532-10, Lasiris, Inc., Quebec, Canada). The laser was 
directed via a dichroic mirror (Z532/780/RPC, Chroma Technologies, San Diego, CA) through a 
40x, 0.75 NA focusing objective (Plan fluor, Nikon, Melville, NY) to a 5 μm spot size in a 50 
μm internal diameter fused silica capillary (Polymicro technologies, Phoenix, AZ)  through 
which the sample flowed at 4.2 cm/s linear velocity. The capillary was mounted on an XYZ 
translational stage.  Greater than 90% of the fluorescence signal generated by Cy5 in the sample 
and collected by the same objective, was transmitted through the dichroic mirror to a second 
dichroic mirror (640DCSPXR, Chroma Technologies, San Diego, CA) which directed the Cy5 
fluorescence emission through longpass and bandpass filters (FEL650/FB670-10 for Cy 5, 
Thorlabs, Newton, NJ). The beam was focused by a 20x objective onto the active area (175 μm) 
of a single-photon counting avalanche diode detector (SPCM-AQR-14, EG &G, Vandreuil, 
Canada). Photon counts were processed by a PCI-6602 data acquisition board (National 
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Instruments, Austin, TX) with a  temporal resolution of 12.5 ns and analyzed using a custom-
made Labview v.7 software (Dr. L. Davis, UT Space Institute, TN). 
 
Figure 5.1: Diagram of the smFRET instrument set-up showing a 532 laser for excitation of the 
fluorophores and a system of dichroic mirrors and filters, and an avalanche diode detector for 
detection Cy5 fluorescence emission.  
 
5.2.5 smFRET data analysis 
To characterize the transit time and demonstrate the presence of non-random correlated 
single photon bursts, autocorrelation analysis was carried out using the Labview software over a 
data set of 50 s.  To distinguish single-molecule events from the background the Microcal Origin 
software was used in determining the frequency of events and for setting a threshold for the 




5.3.1 Effects of an Ethylene Glycol Spacer on the FRET Response of Annealed Cy3 and Cy5 
Labeled Complementary Oligonucleotide  
 
Results of the studies to determine the length of linker for maximum FRET response are 
shown in Figure 5.2. The aim of this research was to utilize the aptamer beacon under single 
molecule conditions. In this regard, factors that enhance FRET intensity, such as the distance 
between the dye molecules in the annealed strands, needed to be optimized to achieve this goal. 
Thus we investigated the effect of attaching the dyes via a short flexible spacer molecule to the 
complementary oligonucleotide sequences on the FRET response generated after the strands 
annealed.  The emission spectra obtained for the different combinations of linker versus no linker 
yielded a higher FRET response for the oligonucleotide pair containing an ethylene glycol linker 
between each oligonucleotide sequence and the attached dye.  Combinations of one linker and no 
linker or no linkers used produced relatively equal FRET responses for the annealed strands. 
Based on the information provided by Integrated DNA Technologies concerning the dyes used, 
the dye labeled oligonucleotide sequences were produced using Cy3 and Cy5 dyes synthesized 
with a three carbon linker for conjugation purposes. By introducing an ethylene glycol spacer 
molecule the effective linker length was increased further by 3 atoms. Thus, the results indicated 
that for maximum FRET to be generated by the oligonucleotide sequence used in this experiment 
a linker of approximately 6 atoms in length is required.  This was taken into consideration in 
synthesizing the aptamer beacons. 
5.3.2 Ensemble FRET Assays of the Aptamer Beacons for Analysis of Thrombin and 
Prothrombin 
 
To determine the effectiveness of the aptamer beacons at selectively measuring thrombin in 
solution, samples of different thrombin or prothrombin concentrations were prepared and mixed 
with a fixed concentration of the two aptamers. Figure 5.3 shows results of variation of FRET 
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response with protein concentration. At 250 nM aptamer concentration an increase in FRET 
response was observed for thrombin from above 25 nM protein.   
 
Figure 5.2: FRET and fluorescence emission spectra for annealed complementary seven-
oligonucleotide sequences and the Cy5-labeled sequences in TBS buffer at pH 7.7. Excitation 
was carried out at 532 nM and the fluorescence emission spectra obtained for Cy5 emission. 
Both oligonucleotide sequences were synthesized with the FRET dyes attached with (represented 
by a prime (‘)) or without an ethylene glycol internal spacer between the dye and the sequence to 
determine the best linker combination for maximum FRET response. 
 
No variation in FRET response was observed for prothrombin indicating specificity of the 
technique for thrombin. The assay required association of both aptamers with the protein 
molecule in order to enhance annealing of the signaling complementary oligonucleotide strands. 
Since exosite II is unavailable in prothrombin the co-association process was hindered leaving 
the FRET response unchanged in the presence of prothrombin.22 We were thus able to ascertain 
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proper functioning of the aptamer beacons for subsequent experiments at the single molecule 
level.  
 
Figure 5.3: Variation in ensemble FRET response for aptamer beacon assays with increasing 
concentration of thrombin or prothrombin in TBS at pH 8.5.  The HD1 and HD22 beacon 
concentrations were fixed at 250 nM. 
 
5.3.3 smFRET Analysis of Thrombin-Aptamer Assays 
The FRET beacons were used in single molecule studies for detection of picomolar levels 
of thrombin in solution. The home-built system was initially optimized for single molecule 
detection using fluorescent beads. To obtain the probe volume and concentration for probability 
of single molecule occupancy, the beam waist was determined experimentally at different sample 
flow rates using an autocorrelation function built into the Labview software. The beam diameter 
was determined to be 4 μm and used to estimate a probe volume between 133 and 222 fL. Based 
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on the results, the concentration of analyte required for single molecule occupancy of the probe 
volume was determined to be 6 pM at a sample linear velocity of 4.244 cm/s.  
 Pre-incubated samples of the aptamer beacons were analyzed after dilution to picomolar 
concentrations and the fluorescence generated by Cy5 was monitored for smFRET occurrence. 
Results of the smFRET analysis are shown in figures 5.4 and 5.5. Figure 5.4 shows photon burst 
data collected over 50 s time intervals for buffer, 30 pM Cy5-HD22, a mixture of the two 
aptamer beacons at 30 pM concentrations and both aptamers pre-incubated with thrombin in a 5 
fold excess aptamer to thrombin ratio.  The amplitude of photon bursts for the buffer and 
aptamer samples were below 4000 counts/s on the average. With the addition of thrombin to the 
sample the amplitude of photon bursts increased above 10P5P counts/s. To eliminate false positives 
due to excitation of Cy5 by the laser and formation of a FRET pair by the aptamer beacons in the 
absence of thrombin, the photon counting threshold was set at 4000 counts/s (see Figure 5.5) and 
the frequency of photon bursts above this threshold computed to determine the number of events 
for smFRET produced for the thrombin-aptamer complex.  At 6 pM thrombin and a 5 fold excess 
of aptamer beacons the frequency of molecular events was 27 above the 4000 counts threshold. 
The expected number of events (NBev B) was calculated from the equation below.23  
NBevB= 2PBoBνT/πω 
Where PBo Brepresents the probability of single molecule occupancy in the probe volume, ν is the 
linear flow velocity (4.2 cm/s), T is the duration of the experiment (50 s) and ω is the laser beam 
diameter (4 μm). Based on a probability of 0.01, NBev B was calculated to be 3342 for the 50 s 
duration, which is far higher than the experimental results obtained. 
Formation of a thrombin aptamer complex is governed by binding kinetics affected by 
the dissociation constant of the complex.  HD22 has a higher affinity for thrombin with a 
dissociation constant (KBDB) of 0.5 nM while that for HD1 is between 1.4 to 100 nM.18  Assuming 
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the KBDB values remain unchanged for both aptamers during complex formation with thrombin, the 
6 pM thrombin and 30 pM aptamer concentrations are well below the K BDB of each aptamer and 
formation of the complex or retention of its structure after dilution during analysis would be 
affected. 
 
Figure 5.4: Computer generated  readouts of the assays showing the rate of photon count with 
time obtained on the Cy5 fluorescence detector for A) buffer only, B) 30 pM Cy5-HD22 beacon 
in buffer, C) 30 pM HD1-Cy3/Cy5-HD22 mixture in buffer and D) 30 pM HD1-Cy3/Cy5-HD22 
with 6 pM thrombin. Samples were prepared in buffer at pH 8.5, incubated at room temperature 
at a higher concentration and diluted to 30 pM aptamer beacon concentration prior to analysis on 
the smFRET system.  
 
Thus, the lower molecular event counts obtained are a result of samples being analyzed at 
concentrations below the KBDB of the aptamers. To enable single molecule detection of low 
thrombin concentrations the probe volume can be adjusted to allow higher sample concentrations 
to be used. By introducing a pinhole in front of the detector, the probe volume can be further 
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decreased. Alternatively, a higher magnification objective with high numerical aperture, such as 
a 100X oil immersion objective can be used to focus the beam to an even smaller diameter. By 
decreasing the probe volume, concentrations of aptamer and thrombin in the nanomolar range 
can be used for sample analysis. 
 
Figure 5. 5: Plots of photon burst data obtained for smFRET analysis of the aptamer assay 
showing the frequency of molecular events obtained at different count rate thresholds for Cy5-




Aptamers have emerged as potential affinity agents that rival or complement antibodies 
in developing diagnostic assays for disease detection. Single molecule detection methods also 
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provide high sensitivity techniques in which aptamers can find use. We have demonstrated the 
use of two aptamers in a FRET-based assay for the detection of low levels of thrombin.  
Sensitivity and reliability of the smFRET assay depends on formation of the complex and its 
stability.  Due to the dissociation constants of the aptamers, low levels of molecular events were 
detected for a 6 pM concentration of thrombin. Future work will involve adjusting the single 
molecule system by eithere the use of a higher magnification lens or use of pinholes to enable 
analysis of higher concentrations of samples. 
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Chapter 6 Conclusions, Current and Future Developments 
6.1 Conclusions 
We have demonstrated the use of aptamers in analytical applications including microchip 
affinity CGE, aptamer sandwich assays on PMMA substrate and smFRET analysis and 
expressed and purified a membrane protein biomarker as a possible target for aptamer selection. 
In the microchip CGE assay aptamers derived towards thrombin were compared to determine the 
one most suited for thrombin quantification in plasma.  The HD22 aptamer with a higher binding 
affinity than HD1 aptamer was able to form well resolved aptamer-thrombin complexes during 
microchip CGE separation. Concentrations as low as 10 nM thrombin could be detected by this 
method. De-salted plasma samples diluted to 10% in running buffer were successfully analyzed 
for thrombin with microchip CGE separations performed in less than one minute.    
We also expressed a histidine-tagged rEpCAM in bacteria and mammalian cells to 
determine the system best suited for large-scaled production of the protein. The episomal 
expression method in Cos 7 cells was selected, due to higher protein yield, for production of 
rEpCAM. To ensure high purity of protein in its native state a selective purification technique 
based on a tandem IMAC with electro elution was developed. Using this purification method 
electrophoretically pure protein was obtained and detected by western blot using an anti-EpCAM 
antibody specific for the native form of EpCAM. This technique may be effective in the 
purification of histidine-tagged proteins expressed in eukaryotic systems in which histidine-rich 
contaminating proteins affect purity of the target protein. 
 Aptamers have an advantage over antibodies due to their chemical and thermal stability, 
ease of chemical modification and resistance to denaturation when immobilized on surfaces. The 
use of an aptamer pair in a sandwich assay format was developed on PMMA substrate using 
thrombin and PDGF aptamers. To increase the capture element density and enhance target 
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binding the immobilization conditions were optimize by using neutral pH and 200 mM EDC 
concentration in the immobilization process.  In the thrombin aptamer assay, HD22 served as the 
capture element due to its higher binding affinity and ability of its immobilized form to maintain 
the G-quartet structure as determined by NMM fluorescence enhancement. The HD1 aptamer 
was dye labeled and served as the detection aptamer.  In the PDGF-BB sandwich assay, the 
aptamer served both as the capture and detection elements due to the homo-dimeric nature of the 
protein.  Results indicated higher sensitivity for the PDGF-BB assay compared to the thrombin 
assay due to the higher binding affinity (KBDB=100 pM) of the PDGF aptamer. However, its linear 
dynamic range was smaller due to competition between the immobilized aptamer and the 
detection aptamer for the protein target. The thrombin sandwich assay had a larger dynamic 
range and since both aptamers recognize different epitopes the binding kinetics was unaffected 
by competition for similar binding sites on the protein. 
Initial results in the development of an aptamer-based smFRET technique for detection of 
low levels of thrombin indicated that aptamers can be effectively utilized for single molecule 
detection of biomolecules. However, detection of the aptamer-protein complex at low picomolar 
concentrations was greatly affected by the dissociation constant of the aptamers. The single 
molecule detection system needs to be optimized to allow utilization of analyte and reagents at 
concentrations above the K BDB of the aptamers. 
6.2 Current Work 
Detection of analytes in the single molecule realm lends sensitivity to analytical 
techniques in the analysis of biomolecules. By decreasing the detection volume, background 
interference is drastically reduced thus increasing the signal-to-noise ratio. In the aptamer-based 
smFRET studies samples of pre-incubated aptamer beacon and thrombin were diluted to low 
picomolar concentrations prior to analysis. With the lowest aptamer beacon KBDB value of 500 pM 
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the concentrations required for single molecule detection were far below concentrations required 
for complex stability or formation.  Detection of the aptamer-thrombin complexes formed in the 
aptamer smFRET assay can be achieved by maintaining the concentrations of the target and 
aptamer beacons in the nanomolar range. This can be achieved by controlling the probe volume 
through focusing the laser beam into a tighter spot. To achieve this, a high magnification 
objective such as an oil-immersion objective with high numerical aperture (NA ~ 1.3) can be 
used to increase resolution.  Alternatively a pinhole can be used to decrease the probe volume to 
about 1 femtoliter.  With this probe volume size analytes in nanomolar concentration range can 
be used for single molecule detection.  
Current modifications are underway to decrease the laser beam diameter for the home-
built single molecule system by the use of a pinhole or replacing the 40x objective with a 100x 
oil-immersion objective lens.  With these modifications smFRET detection of aptamer-thrombin 
complexes will be easily accomplished thereby increasing the scope of analytical applications of 
aptamers.  
6.3 Future Developments 
The need for generating more aptamers with high specificity for targets has given rise to 
automation of the SELEX process and utilization of microfluidic devices for the aptamer 
generation process.P1, 2 P  A high throughput process for SELEX of protein targets involving 
integrated purification and selection methods on polymeric microfluidic platform would further 
enhance aptamer generation for multiple targets.  A simple microfluidic device for IMAC 
purification and aptamer selection containing nanoposts functionalized with tetradenate chelating 
groups for immobilizing nickel or cobalt ions can be designed for purification and 
immobilization of polyhistidine tagged proteins (see Figure 6.1).  
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Figure 6. 1: Diagrammatic representation of the layout of a simple polymeric microdevice for 
immobilizaton and  purification of histidine-tagged proteins with subsequent electrophoretic 
separation of complexes formed with nucleic acid strands in a degenerate library for aptamer 
selection. Reservoir A contains nanoposts functionalized with tetradentate chelating groups for 
immobilized metal afinity  purification in channel AB with channel CD as the separation 
channel. 
 
Histidine-tagged protein targets can be captured on the IMAC nanoposts and purified by washing 
with the appropriate buffers in the purification channel (AB in Figure 6.1). The purified target is 
then incubated with a random library and the washing steps performed to remove unbound target 
as is performed in the SELEX process. Alternatively, the mixture of oligonucleotides and protein 
target can be directly injected, after the incubation period, into the cross-section of the device 
and separated in the separation channel (CD in figure 6.1) by non-equilibrium capillary 
electrophoresis.P3 P  For simultaneously processing several targets a multichannel version of the 
microdevice could be designed. The microfluidic format for aptamer selection enables utilization 
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